

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371	ATTORNEY'S DOCKET NUMBER: WCM.69.US
	U.S. APPLN. NO. (If known, see 37 CFR 1.52) 09/831142

INTERNATIONAL APPLICATION NO.:
PCT/GB99/03654

INTERNATIONAL FILING DATE:
5 NOVEMBER 1999

PRIORITY DATE CLAIMED:
7 NOVEMBER 1998

TITLE OF INVENTION: PROTEIN AND DNA CODING THEREFOR

APPLICANT(S) FOR DO/EO/US: Anthony Keith CAMPBELL

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau. (see attached copy of PCT/IB/308)
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Item 11. to 16. below concern document(s) or information included:
11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 13. ☒ A **FIRST** preliminary amendment.
 14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
 14. ☐ A substitute specification.
 15. ☐ A change of power of attorney and/or address letter.
 16. ☒ Other items or information:

International Search Report
PCT/IB/308
PCT/IPEA/409
Sequence Listing with Disk in Readable Format
Application Data Sheet



U.S. APPLICATION NO. (If known, see 37 CFR 1.51)

09/831142

INTERNATIONAL APPLICATION NO.
PCT/GB99/03654ATTORNEY'S DOCKET NO.
WCM.69.US17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 1,000.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS

NUMBER FILED

NUMBER EXTRA

RATE

\$

Total claims

30 - 20 =

10

X \$18.00

\$

180.00

Independent claims

7 - 3 =

4

X \$80.00

\$

320.00

MULTIPLE DEPENDENT CLAIMS(S) (if applicable)

+ \$270.00

\$

TOTAL OF ABOVE CALCULATIONS =

\$

1,360.00

Reduction of 1/2 for filing by small entity, if applicable. Applicant claims Small Entity Status under 37 CFR 1.27.

+

\$

680.00

SUBTOTAL =

\$

680.00

Processing fee of \$130 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.49(f)).

\$

TOTAL NATIONAL FEE =

\$

680.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property+

\$

40.00

TOTAL FEES ENCLOSED =

\$

720.00

Amount to be
refunded:

charged:

a. ☒ A check in the amount of \$ 720.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. **25-0120** in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required by 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. **25-0120**. A duplicate copy of this sheet is enclosed.

SEND ALL CORRESPONDENCE TO:

Customer No. **000466**YOUNG & THOMPSON
745 South 23rd Street
2nd Floor
Arlington, VA 22202
(703) 521-2297 facsimile (703) 685-0573


May 7, 2001

By

*Benoît Castel*Benoît Castel
Attorney for Applicant
Registration No. 35,041

JC07 Rec'd PCT/PTO 13 NOV 2001

PATENTS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Anthony Keith CAMPBELL

Serial No. 09/831,142
(PCT/GB99/03654)

Box PCT
Attention: DO/EO

Filed May 7, 2001

PROTEIN AND DNA CODING THEREFOR

AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Notification of Missing Requirements
mailed September 20, 2001, please amend the above-identified
application as follows:

IN THE SPECIFICATION:

Kindly replace the specification originally filed with
the attached substitute specification, provided in clean and red-
lined versions.

IN THE CLAIMS:

Amend claim 2 as follows:

2. (amended) A sequence according to claim 1, wherein
the sequence that encodes for apopholasin is as shown in Figure
4B (SEQ ID NO: 1).

09831142-0001
TO:CGO ATTACHED

Amend claim 3 as follows:

3. (amended) A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in any one of Figures 1, 2, 3, 4A, 6 or 9 (encompassing SEQ ID NOS 1-6 and 23).

Amend claim 12 as follows:

12. (amended) An isolated, purified or recombinant polypeptide according to claim 11 comprising the amino acid sequence of Figure 4 or Figure 5 (SEQ ID NOS 1 and 4-6).

Kindly make of record the attached substitute Sequence Listing, submitted in paper and disc formats.

REMARKS

The Notification of Missing Requirements mailed September 20, 2001, called for submission of a substitute Sequence Listing. A suitable substitute Sequence Listing has been prepared and is submitted herewith, in paper and disc formats.

Applicant hereby states that the content of the paper and disc versions of the Sequence Listing is the same, and that these introduce no new matter into the present application.

Additionally, the specification has been revised to introduce the sequence identification numbers at appropriate

0923443 050701

locations, pursuant to the Sequence Listing requirements. As there are 42 sequences in the present application, the nature of the amendments to the specification were sufficiently extensive that it was considered expedient to prepare a substitute specification. Consequently, also attached to the present amendment is a substitute specification, both in clean form and in "red-line" form, the latter showing the nature of the amendments to the specification relative to the original specification.


It is believed that this paper complies with the requirements set forth in the Notification of Missing Requirements mailed September 20, 2001, such that the application is now in condition for examination on the merits. Such action is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

YOUNG & THOMPSON

By


Andrew J. Patch
Attorney for Applicant
Registration No. 32,925
745 South 23rd Street
Arlington, VA 22202
Telephone: 521-2297

November 13, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claim 2 has been amended as follows:

2. (amended) A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in Figure 4B (SEQ ID NO: 1).

Claim 3 has been amended as follows:

3. (amended) A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in any one of Figures 1, 2, 3, 4A, 6 or 9 (encompassing SEQ ID NOS 1-6 and 23).

Claim 12 has been amended as follows:

12. (amended) An isolated, purified or recombinant polypeptide according to claim 11 comprising the amino acid sequence of Figure 4 or Figure 5 (SEQ ID NOS 1 and 4-6).

09031412.050701

09/831142

JC08 Rec'd PCT/PTO 07 MAY 2001
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Anthony Keith CAMPBELL

Serial No. (unknown)

Filed herewith

PROTEIN AND DNA CODING THEREFOR

PRELIMINARY AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to calculation of the filing fee, please substitute Claims 1-30 as originally filed, with Claims 1-30 as filed in the Article 34 amendment of December 7, 2000. The pages containing Claims 1-30 are marked "AMENDED SHEET" and are attached hereto. Following the insertion of Claims 1-30, please amend these claims as follows:

IN THE CLAIMS:

Amend claim 4 as follows:

--4. (Amended) A sequence according to claim 1, wherein the apopholasin is non-glycosylated.

Amend claim 5 as follows:

--5. (Amended) A sequence according to claim 1, wherein the apopholasin is glycosylated.

Amend claim 8 as follows:

--8. (Amended) A construct according to claim 6, wherein the apophotoprotein is apopholasin.

09831142-050301
T02050-2411860

Anthony Keith CAMPBELL

Amend claim 9 as follows:

--9. (Amended) A recombinant construct according to claim 1, wherein the nucleic acid sequence is linked operably with nucleotides enabling expression and secretion of the apopholasin in a cellular host.

Amend claim 10 as follows:

--10. (Amended) DNA or RNA according to claim 1.

Amend claim 13 as follows:

--13. (Amended) The apopholasin according to claim 11 when expressed by recombinant DNA or RNA according to claim 10.

Amend claim 15 as follows:

--15. (Amended) A cell, plasmid, virus or live organism having incorporated expressibly therein a sequence according to claim 1, whereby it is capable of producing an apoprotein.

Amend claim 16 as follows:

--16. (Amended) A vector comprising a sequence according to claim 1.

Amend claim 18 as follows:

--18. (Amended) A bioluminescent oxidative indicator protein (BOIP), comprising an apophotoprotein according to claim 11 in association with a luciferin.

Amend claim 23 as follows:

--23. (Amended) A method according to claim 21, wherein said BOIP is selected from native or chemically-or

Anthony Keith CAMPBELL

genetically-modified BOIP or a 'rainbow protein' based on such a BOIP.

Amend claim 24 as follows:

--24. (Amended) A method according to claim 21, wherein said BOIP includes a signal peptide, targeting it to a pre-determined extra-or intra-cellular site.

Amend claim 25 as follows:

--25. (Amended) A method according to claim 21, comprising incubating a test sample with a cell, plasmid, virus or live organism having incorporated expressibly therein:

(a) a sequence that encodes the apophotoprotein of pholasin (alternatively, 'apopholasin');

(b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or

(c) a sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or

(d) an oligonucleotide specific for any of the sequences (a), (b) or (c) PROVIDED THAT such homologous sequences according to (b) or (c) encode a protein capable of binding to luciferin.

Amend claim 26 as follows:

--26. (Amended) A method according to claim 21, wherein light emission takes place in the absence of a luciferase.

Anthony Keith CAMPBELL

Amend claim 27 as follows:

--27. (Amended) The use of a sequence or a protein according to claim 1 in the detection, diagnosis or measurement of oxygen or a metabolite thereof.

Amend claim 29 as follows:

--29. (Amended) A method for obtaining a substantially homologous source of apopholasin, which method comprises culturing cells having incorporated expressibly therein a polynucleotide encoding apopholasin as defined in claim 1, and thereafter recovering the cultured cells.

Amend claim 30 as follows:

--30. (Amended) A method, use or kit according to claim 20, substantially as hereinbefore described with particular reference to the Examples.--

R E M A R K S

The above changes in the claims merely place this national phase application in the same condition as it was during Chapter II of the international phase, with the multiple dependencies being removed. Following entry of this amendment by substitution of the pages, only claims 1-30 remain pending in this application.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

Anthony Keith CAMPBELL

Respectfully submitted,

YOUNG & THOMPSON

By *Benoît Castel*
Benoît Castel
Attorney for Applicant
Customer No. 000466
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

May 7, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The claims have been amended as follows:

4. (Amended) A sequence according to ~~any preceding~~ claim 1, wherein the apopholasin is non-glycosylated.

5. (Amended) A sequence according to ~~any preceding~~ claim 1, wherein the apopholasin is glycosylated.

8. (Amended) A construct according to claim 6 ~~or~~ ~~claim 7~~, wherein the apophotoprotein is apopholasin.

9. (Amended) A recombinant construct according to ~~any one of claims 1 to 8~~, wherein the nucleic acid sequence is linked operably with nucleotides enabling expression and secretion of the apopholasin in a cellular host.

10. (Amended) DNA or RNA according to ~~any of claims~~ ~~1 to 9~~.

13. (Amended) The apopholasin according to claim 11 ~~or claim 12~~ when expressed by recombinant DNA or RNA according to claim 10.

15. (Amended) A cell, plasmid, virus or live organism having incorporated expressibly therein a sequence according to ~~any one of claims 1 to 10~~, whereby it is capable of producing an apoprotein.

16. (Amended) A vector comprising a sequence according to ~~any one of claims 1 to 10~~.

18. (Amended) A bioluminescent oxidative indicator protein (BOIP), comprising an apophotoprotein according to ~~any one of claims 11 to 14~~ in association with a luciferin.

0983142-030701

Anthony Keith CAMPBELL

23. (Amended) A method according to claim 21 ~~or 22~~, wherein said BOIP is selected from native or chemically-or genetically-modified BOIP or a 'rainbow protein' based on such a BOIP.

24. (Amended) A method according to ~~any one of~~ claims 21 ~~to 23~~, wherein said BOIP includes a signal peptide, targeting it to a pre-determined extra-or intra-cellular site.

25. (Amended) A method according to ~~any one of~~ claims 21 ~~to 23~~, comprising incubating a test sample with a cell ~~according to claim 15 or with a membrane preparation derived therefrom~~, plasmid, virus or live organism having incorporated expressibly therein:

(a) a sequence that encodes the apophotoprotein of pholasin (alternatively, 'apopholasin');

(b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or

(c) a sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or

(d) an oligonucleotide specific for any of the sequences (a), (b) or (c) PROVIDED THAT such homologous sequences according to (b) or (c) encode a protein capable of binding to luciferin.

Anthony Keith CAMPBELL

26. (Amended) A method according to ~~any one of~~ claims 21 ~~to 24~~, wherein light emission takes place in the absence of a luciferase.

27. (Amended) The use of a sequence or a protein according to ~~any one of~~ claims 1 ~~to 19~~ in the detection, diagnosis or measurement of oxygen or a metabolite thereof.

29. (Amended) A method for obtaining a substantially homologous source of apopholasin, which method comprises culturing cells having incorporated expressibly therein a polynucleotide encoding apopholasin as defined in ~~any one of~~ claims 1 ~~to 10~~, and thereafter recovering the cultured cells.

30. (Amended) A method, use or kit according to ~~any one of~~ claims 20 ~~to 29~~, substantially as hereinbefore described with particular reference to the Examples.

1. An isolated, purified or recombinant nucleic acid sequence comprising:

(a) a sequence that encodes the apophotoprotein of pholasin (alternatively, 'apopholasin');

(b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or

(c) a sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or

(d) an oligonucleotide specific for any of the sequences (a), (b) or (c)

PROVIDED THAT such homologous sequences according to (b) or (c) encode a protein capable of binding to luciferin.

2. A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in Figure 4B.

3. A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in any one of Figures 1, 2, 3, 4A, 6 or 9.

4. A sequence according to any preceding claim, wherein the apopholasin is non-glycosylated.

5. A sequence according to any preceding claim, wherein the apopholasin is glycosylated.

6. An isolated, purified or recombinant construct incorporating a sequence encoding an apophotoprotein whose expression in a substrate, in association with a luciferin therefor, signals the presence of oxygen or an oxygen metabolite in the substrate.

7. An isolated, purified or recombinant construct incorporating a sequence encoding an apophotoprotein whose expression in a substrate, in association with a luciferin therefor, signals the presence of oxygen or an oxygen metabolite in the absence of a corresponding luciferase in the substrate.

8. A construct according to claim 6 or claim 7, wherein the apophotoprotein is apopholasin.

9. A recombinant construct according to any one of claims 1 to 8, wherein the nucleic acid sequence is linked operably with nucleotides enabling expression and secretion of the apopholasin in a cellular host.

10. DNA or RNA according to any of claims 1 to 9.

11. An isolated, purified or recombinant polypeptide comprising apophotopro:
pholasin (apopholasin), or a mutant or variant thereof, which mutant or variant is capable
of binding to luciferin.
12. An isolated, purified or recombinant polypeptide according to claim 11
5 comprising the amino acid sequence of Figure 4 or Figure 5.
13. The apopholasin according to claim 11 or claim 12 when expressed by
recombinant DNA or RNA according to claim 10.
14. The apopholasin according to claim 13, which is non-glycosylated.
15. A cell, plasmid, virus or live organism having incorporated expressibly therein a
10 sequence according to any one of claims 1 to 10, whereby it is capable of producing an
apoprotein.
16. A vector comprising a sequence according to any one of claims 1 to 10.
17. A host cell transformed or transfected with a vector according to claim 16.
18. A bioluminescent oxidative indicator protein (BOIP), comprising an
15 apophotoprotein according to any one of claims 11 to 14 in association with a luciferin.
19. A BOIP according to claim 18, wherein the luciferin is derived from *Pholas
dactylus*.
20. A method for the preparation of a bioluminescent oxidative indicator protein
20 (BOIP), which method comprises bringing an apophotoprotein into association with a
luciferin therefor.
21. A method for the detection and/or measurement of oxygen or one of its
metabolites extracellularly, which method comprises providing a bioluminescent
oxidative indicator protein (BOIP) extracellularly and thereafter detecting and/or
quantifying light emission therefrom and/or changes in colour, intensity and/or
25 polarisation of emission(s), wherein the apophotoprotein comprises recombinant
apopholasin.
22. A method for the detection and/or measurement of oxygen or one of its
metabolites in live cells (intracellularly), which method comprises providing a BOIP
intracellularly and thereafter detecting and/or quantifying light emission therefrom and/or
30 changes in colour, intensity and/or polarisation of emission(s) therefrom.
23. A method according to claim 21 or 22, wherein said BOIP is selected from native
or chemically- or genetically- modified BOIP or a 'rainbow protein' based on such a
BOIP.

24. A method according to any one of claims 21 to 23, wherein said BOIP includes a signal peptide, targetting it to a pre-determined extra- or intra- cellular site.

25. A method according to any one of claims 21 to 23, comprising incubating a test sample with a cell according to claim 15 or with a membrane preparation derived therefrom.

26. A method according to any one of claims 21 to 24, wherein light emission takes place in the absence of a luciferase.

27. The use of a sequence or a protein according to any one of claims 1 to 19 in the detection, diagnosis or measurement of oxygen or a metabolite thereof.

28. A diagnostic kit incorporating a sequence or protein according to any one of claims 1 to 19.

29. A method for obtaining a substantially homologous source of apopholasin, which method comprises culturing cells having incorporated expressibly therein a polynucleotide encoding apopholasin as defined in any one of claims 1 to 10, and thereafter recovering the cultured cells.

30. A method, use or kit according to any one of claims 20 to 29, substantially as hereinbefore described with particular reference to the Examples.

09831142.050701

PROTEIN AND DNA CODING THEREFOR

JC08 Rec'd PCT/PTO 07 MAY 2001

The present invention relates to a protein, capable of bioluminescence, cDNA coding therefor and their uses, *inter alia*, in diagnostics and therapy. In particular, this invention relates to the cloning and sequencing of cDNA coding for pholasin from the bivalve mollusc *Pholas dactylus*.

The term 'bioluminescence' refers to the emission of light resulting from a chemical reaction within, or produced by, a living organism. The essential components to the chemical reaction are: an organic molecule, usually comprising a luciferin; oxygen or one of its metabolites; and an enzyme or luciferase that catalyses the oxidation of the luciferin. The chemiluminescent reaction responsible for bioluminescence may be represented as follows:

Luciferin + O₂, or O₂⁻, or H₂O₂, or ·OH or OCl⁻ or OX⁻ or ¹O₂ (+ luciferase) → oxyluciferin + light.

Up to three other substances may also be required to generate light or to generate light of the required colour and intensity. These are as follows:

- (a) A cation, such as H⁺, Ca²⁺, Mg²⁺ or a transition metal cation (eg Cu⁺/Cu²⁺, Fe²⁺/Fe³⁺, La³⁺ and V³⁺);
- (b) A co-factor such as NAD(P)H, FMN or ATP; and/or
- (c) A fluor as an energy transfer acceptor.

Five chemical families of luciferin are known:

- (a) Aldehydes (found in the freshwater limpet *Latia*, earthworms, and with FMN in bacteria);
- (b) Imidazolopyrazines, which are the compounds most commonly responsible for bioluminescence in the sea (found in Sarcomastigophora, Cnidaria, Ctenophora, Annelida, Chaetognatha, some Arthropoda, some Mollusca and some Chordata);
- (c) Benzothiazoles (found in beetles such as fireflies and glow-worms);

- (d) Linear tetrapyrroles (found in dinoflagellates, euphausiid shrimp and some fish);
and
- (e) Flavins (found in bacteria, fungi, polychaete worms and some molluscs).

5 Chemiluminescent reactions involving these luciferins may produce a glow or a flash with an emission of violet, blue, blue-green, green, yellow, orange or red light, or occasionally UV or IR light. The light emission may be linearly or circularly polarised. The luciferin or its product may also be detected and quantified by fluorescence or phosphorescence. As a chemical reaction is directly responsible for the light emission, it does not require
10 exposure to UV, visible or IR light. However, some bioluminescent systems, such as that in the red organ of the deep sea fish *Malacosteus*, exhibit a photo-chemiluminescence, where light can trigger or enhance the chemiluminescent reaction. [Reference is directed to Chemiluminescence: Principles and Applications in Biology and Medicine, A K Campbell (1988), Horwood/VCH Chichester, Weinheim.]

15 In the case of some bioluminescent proteins, the luciferin is so tightly or covalently bound to the protein molecule that it does not diffuse away into the surrounding fluid as a result of the chemiluminescent reaction. In this case, the protein-luciferin complex is known as a photoprotein; and the protein itself is referred to as an apophotoprotein. Some
20 bioluminescent proteins are proteins whose light emission or radiation depends on or may be altered by oxygen or one of its metabolites; these bioluminescent proteins are hereinafter referred to as 'bioluminescent oxidative indicator proteins' (BOIPs). BOIPs may thus be photoproteins or luciferin-luciferase systems.

25 BOIPs, therefore, may be used to detect and quantify oxygen or one of its metabolites in individual cells, defined compartments of living cells such as the nucleus, whole organs and organisms - both animals and plants, including microbes such as viruses and bacteria and protozoa - as well as substances of biological interest such as substrates, metabolites, vitamins, drugs, intra- and extra-cellular signals, enzymes, antigens, antibodies and
30 nucleic acids. Heretofore, it has only been known to employ native BOIPs extracellularly.

The present invention therefore relates to a method for the detection and/or measurement

of oxygen or one of its metabolites in live cells (intracellular), which method comprises providing a BOIP, such as native or chemically- (or genetically-) modified BOIP or a 'rainbow protein' based on such a BOIP, intracellularly and thereafter detecting and/or quantifying light emission therefrom and/or changes in colour, intensity and/or polarisation of emission(s) therefrom.

Furthermore, it has now been found that, by sequencing the BOIP and identifying the cDNA encoding therefor, the recombinant BOIP can also be used in such a method, or chemically- or genetically-modified recombinant BOIP, or a 'rainbow protein' based on such a BOIP. For example, the bivalve mollusc *Pholas dactylus* has been shown to comprise a native photoprotein, which interacts with a luciferase, when they are secreted together by the mollusc to produce light when O_2 or one of its metabolites is present. References to the Purification and Properties of *Pholas Dactylus* Luciferin and Luciferase can be found by Michelson in Methods in Enzymology LVII 385-406 (1978). References to detection of activation of neutrophils by detection of superoxide anion can be found by Roberts in Anal Biochem 160 139-148 (1987) and by Müller *et al* in J Biol Chem 264 105-113 (1989). The native photoprotein (known as pholasin) is made up of a glycosylated apoprotein (34kDa) with a small organic molecule, the luciferin, tightly bound to it. This luciferin (whose structure is unknown - Müller and Campbell in J Biol Chem 265 25-30 (1990)) can be extracted from the protein moiety - the apopholasin - or from the organism by a standard treatment, such as mild acid. The pholasin may be collected from live molluscs found in sedimentary rocks at low water along the south coast of England from Plymouth to Folkestone and also along the French channel coast and in the Mediterranean. Further details may be obtained from marine fauna and the references cited herein.

We have surprisingly found that pholasin can generate light even without the presence of the corresponding luciferase by addition of oxygen metabolites such as O_2^- , H_2O_2 , OCl^- or other oxyhalide anions, or organic peroxides, and certain organic solvents such as dimethyl sulphide (DMSO) or dimethyl formamide (DMF).

We have now identified the cDNA encoding for the (non-glycosylated) apoprotein of pholasin, which may also be called 'apopholasin'. Accordingly, the present invention

therefore further provides an isolated, purified or recombinant nucleic acid sequence comprising:

- (a) The apophotoprotein of pholasin (alternatively, 'apopholasin');
- 5 (b) A sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or
- (c) A sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or
- (d) An oligonucleotide specific for any of the sequences (a), (b) or (c).

10

The present invention will now be further described with reference to the accompanying Figures, in which:

15 Figure 1 shows three different cDNAs encoding apopholasin, referred to as clones 40, 3 and 5. Nucleotides in bold type show codons used for initiation and termination of translation;

20 Figure 2 shows the three sequences of Figure 1 aligned to demonstrate the sequence similarity. This figure was generated by Clustal. Positions which are indicated with a star are identical in all three clones. The codons for the initiation and termination of translation are highlighted in bold;

25 Figure 3 shows the oligonucleotides used for the complete sequencing of the positive clones. These were identified from the cDNA library; their positions in clone 40 are shown. Oligonucleotides are shown in bold type, portions of the flanking sequence of the Bluescript plasmid are shown in italic type;

30 Figure 4 describes the protein sequence described by the DNA sequence coding for apopholasin and shows, in Figure 4A, the complete sequence of the positive clone 40 identified from the *Pholas dactylus* light organ library. The first 20 amino acids at the N-terminus are a signal peptide, and this can either be retained or removed when generating the BIOP as described in this invention and, in Figure 4B, the cDNA coding for apopholasin with untranslated 5' and 3' ends. The untranslated regions are also shown;

Figure 5 describes the protein sequence for pholasin with (5B) and without (5A) the signal peptide;

- 5 Figure 6 shows the sequence for apopholasin genomic DNA. Two gDNA clones were indentified but no introns were found; the Figure shows an alignment of the cDNA from cDNA clone 40 and the gDNA amplified by both *rTth* DNA polymerase XL and BioXAct polymerase. The sequences of the PCR product and the inserts in pGEM T were aligned with the sequence of the cDNA of clone 40 and were identical to this cDNA;
- 10 Figure 7 describes the oligonucleotides used for screening and expression. Degenerate oligonucleotides for library screening are shown in Figure 7A; non-degenerate ones in Figure 7B; and oligonucleotides used for protein expression are shown in figure 7C; Figure 8 lists the main restriction sites in the DNA for engineering pholasin; Figure 9 is a schematic representation of Figure 8 mapped to the sequence of Figure 4A
- 15 (translated region), and Figure 10 is a time course of hypo-chlorite triggered chemiluminescence.

Accordingly, the present invention provides recombinant DNA encoding the apophotoprotein apopholasin and comprising the nucleotide sequence of the sequence disclosed in Figure 4B. Three different cDNAs coding for apopholasin have been

20 isolated, having differing non-coding regions, respectively disclosed in Figure 1. The genomic DNA (gDNA), which contains no introns, has been shown (Figure 6) to comprise the same basic sequence as the cDNA.

Pholasin is a glycoprotein having 11.1 glusamine, 9.8 fructose, 7.1 mannose and 5.2

25 galactose residues. The cDNA for apopholasin has a molecular weight of 23,456 compared to 34,600 of the pholasin extracted from *Pholas*. The difference in the molecular weights of native versus recombinant apopholasin is due to the glycosylation of the native protein and luciferin. The isoelectric point of the translated protein calculated by the ISOELECTRIC command of the GCG programme is at 3.84. The native protein

30 has a lower isoelectric point (<3.5), probably due to the presence of bound sulphate.

The three clones (Figure 2) isolated from the library encode a unique protein (Figures 4 and 5), which does not have the same amino acid sequence as any known protein in the SwissProt database. The present invention therefore not only provides cDNA and RNA

coding for the protein, but also the recombinant protein *per se*, with or without glycosylation units. A comparison of segments of the pholasin protein sequence with the proteins in the SwissProt database identified several proteins with regions having a high sequence similarity to regions of the cloned protein. These included several proteins which interact with nucleotides (Table 1).

Table 1 *A comparison of sections of the sequence of the cloned protein with sections of proteins which interact with nucleotides.*

Protein	Homologous region cloned protein homology (+ denotes a conserved amino acid) selected protein
tRNA-splicing endonuclease β subunit <i>Saccharomyces cerevisiae</i> EC 3.1.27.9	SLYDEDNNGVMDEGKVIPSETIE +L DEDNN + + G ++P E++E NLRDEDNNLLDENGDLLPLESLE LDQDVELDYTW LD DV DYTW LDHDVSKDYTW
ATP-AMP transphosphorylase <i>Cyprinus carpio</i> EC 2.7.4.3	VMDEGKVIPSETIEDDIKDCGLLDQDVELDY +M +G+++P +T+ D IKD + DV Y IMQKGELVPLDTVLDMIKDAMIADVSKGY
DNA primase <i>Synechocystis sp.</i> EC 2.7.7. -	EEVQCAMNWTQANEYVFNV ++VQ M ++Q+ + +FN D DQVQSLMRFSQSKQIIFNFD
purine permease <i>Emmericella nidulans</i>	VQCAMNWTQANEYV + C+++WT+ N ++ IMCSVDWTRRNRFI
DNA repair protein complementing XP-A cells homologue <i>Drosophila melanogaster</i>	PDTVDEAEDTPSET PDT DE EDT + T PDTYDEEEDTYTHT
ATP synthase β chain <i>Peptococcus niger</i> EC 3.6.1.34	DTVDEAEDTPSET D +DEA + PSET DPIDEAGEVPSET
DNA polymerase α <i>Homo sapiens</i> EC 2.7.7.7	DEDNNGVMDEGKVIPSETIEDDIKD D+D G +++G+ I + +EDD D DDDGIGYVEDGREIFDDDLEDDALD

Similarity was found between the *Vargula* luciferase and *Renilla* LBP, but no other bioluminescent protein.

Sequence homology between the cloned protein and (a) *Vargula* luciferase (b) *Renilla* LBP. An area of high homology in all three proteins is in bold print.

5

(a) 148 206

GTIVVT**VRVSLY**DEDNNGVMDEGKVIPSETIEDDIKDCGLLD-QDVELDYTWQTQNECDL

V+VSL D + + + T+ D I D + V++ + +

YWNTWD**VKVSLR**DVESYTEVEKYTIRKQSTVVDLIVDGKQVKVGGVDVSI PYSSSENTSI

10 353

412

(b)

105

166

STMPGTYMLMDVCATRDADDKCIEGTIVVT**VRVSLY**DEDNNGVMDEGKVIPSETIEDDIKDC

+ TR + **VR+S+** + N+ K I

15

AIKIAKLSAEKAEETRGLRVADQLGLAPG**VRISV**EEAAVNATDSL LKMKAEKAMAVIQSL

41

104

Three potential glycosylation sites on the protein have the consensus triplet sequence Asn-Xaa-Ser/Thr (where Xaa can be any residue except proline). Thr 216 was identified as a potential site of O-linked glycosylation by a neural network which has been trained to identify this type of glycosylation. The amino acid sequence was also entered into a neural network which had been trained to identify eukaryotic signal peptides. This confirmed that the most likely cleavage site is between positions 20 and 21 (GSG-EE).

Many families of proteins contain a "signature" sequence of amino acids. The sequence of the clones did not contain any of these signatures present in the PROSITE database. The amino acids from 170 to 185 correspond to the calcium binding consensus sequence [DENQST]X[DENQST]X[DENQST]X[DENQST]X[DENQST]XX[DENQST]. Thirteen potential phosphorylation sites were discovered that matched the consensus sequences for either the kinase phosphorylation site [RK](2)-x-[ST], the protein kinase C phosphorylation site [ST]-x[RK] or the casein kinase II phosphorylation site [ST]-x(2)-[DE].

Three N-linked glycosylation sites were identified in the translated sequence of the clones A neural network has been trained to identify this type of glycosylation which identified Thr

216 as a potential site of O-linked glycosylation. At least one of these sites must be glycosylated in the native protein in order to account for the presence of the sugar residues. A putative signal peptide region preceded the N terminus of the secreted protein (determined by amino acid sequencing and was identified as a signal peptide by a neural network). To confirm this result the protein sequence was searched with PSORT for motifs which would locate the cloned protein in a cellular compartment. The protein sequence did not contain any transmembrane regions or N-myristoylation patterns which would indicate the presence of a lipid anchor. No targeting or retention sequences were found for the nucleus, mitochondria, endoplasmic reticulum or peroxisome.

The fact that the clones had some sequence similarity with proteins that interact with nucleotides may suggest that pholasin binds a co-factor as part of the chemiluminescent reaction. Beetle luciferases require ATP binding for chemiluminescent activity. There is no P-loop binding motif ((A,G)x4GK(S,T) or (A)x{4}GK(T)) in the amino acid sequence of these clones. However, not all ATP binding proteins contain this motif. Neither does the cloned protein contain the GXGXXG phosphate binding consensus sequence necessary for the binding of other co-factors such as nicotinamide adenine dinucleotide.

The amino acid and sugar components of pholasin are not able to emit light at the wavelength of the native protein (490nm). This indicates that there must be a chromophore bound to the protein. There are, however, proteins in which the chromophore is composed of modified amino acid residues within the polypeptide. The best characterised of these is the green fluorescent protein (GFP). This has a chromophore which is a ring formed by the autocatalytic cyclisation of the residues Ser-dehydroTyr-Gly. The serine may be mutated to a threonine, which increases the amplitude of the emission at 488nm. Pholasin had no similar amino acid sequence. Putative luciferin binding regions have been identified for two bioluminescent chemistries. Aequorin has a putative coelenterazine binding region, which is also present in two sections of the *Vargula hilgendorffii* luciferase. The sequence of the cloned protein has no homology to the putative luciferin binding site of aequorin, but the region of the *Vargula* luciferase from residue 353 to 411 has some similarity, as does the LBP of *Renilla reniformis*, which also binds an imidazolopyrazine. This may indicate that the chemistry of pholasin bioluminescence involves an imidazolopyrazine luciferin. However, the region of homology is very small. The beetle luciferases contain an area of

low sequence homology which may bind the benzothiazole luciferin. This low homology may account for the different colours of beetle bioluminescence. used a luciferin analogue (2-(4-benzoylphenyl) thiazole-4-carboxylic acid which photoinactivated the luciferase active site of the firefly *Photinus pyralis*. This photoinactivation was directly linked to the degradation of a small peptide sequence HHGF (residues 244-257). This is therefore postulated as a luciferin-binding site. The cloned protein does not have any sequence homology with these putative binding regions. Two strongly conserved regions of amino acids have also been found in both the luciferase and the luciferin binding protein of the dinoflagellate *Gonyaulax polyedra*. These regions were compared to the cloned protein, but no sequence similarity was found. No sequence identity could be established between the bacterial luciferases and the cloned protein.

Therefore, the present invention provides cloned apophotoprotein apopholasin (and the cDNA coding therefor), which has identical properties to native (but non-glycosylated) apopholasin with respect to molecular weight, amino acid composition, potential for glycosylation, its highly acidic pI and its cellular location. Hence, the present invention can further provide the corresponding BOIP or modified BOIP, according to standard methods.

The corresponding BOIP is preparable by bringing the apophotoprotein pholasin into association with the luciferin, also using standard methods. Although the luciferin is tightly bound in the native pholasin BOIP, it has been found that it may not be the case in the recombinant pholasin BOIP; indeed the luciferin may be weakly bound or merely present with the apoprotein. For example, a methanol, aqueous, acidic or other extract of *Pholas dactylus* (whole organism or light organ dissected from the animal) containing the 'luciferin', or the pure luciferin, may be added to the solution, cell or organism (Figure 10 shows the time course of hypo-chlorite triggered luminescence in these circumstances). A time course of apopholasin reactivation was performed by incubating partially purified recombinant pholasin secreted by insect cells with acid:methanol extract of *Pholas dactylus* (●) for 0 (solid line), 1 (---), 2 (-- —), 6(- —) or 24 hours (— —), or incubated without extract (○). Controls of buffers only with no protein or acid:methanol extract () and extract alone (■) were treated in identical conditions. Chemiluminescence was

triggered by the addition of 2% sodium hypochlorite at 10 seconds (arrow) and is shown as chemiluminescent counts minus background light. A typical curve obtained by hypochlorite triggering of native pholasin is also shown (X). A representative experiment carried out in duplicate is shown.

5

The luciferin associates with the apo-BOIP forming the photoprotein or remains loosely bound so that it turns over like a luciferase. The luciferin on the photoprotein then reacts with oxygen or one of its metabolites to produce light, in the presence or absence of the luciferase. The light emission may be detected, quantified, or imaged using a
10 luminometer, photographic film or imaging camera, or by the naked eye. Alternatively, light emission may be generated spontaneously by intra- or extra-cellular metabolites reacting with the apo-BOIP.

Although illustrated with respect to pholasin, the following may apply to any BOIP: the
15 BOIP can be produced directly from native DNA, or from DNA engineered or amplified by the polymerase chain reaction. By this means, sites can be inserted within the protein by splitting the DNA into two or more pieces, or by adding DNA sequences to the 5' or 3' ends. For example, the DNA may be expressed in bacteria, yeast, an insect or human cell, or other suitable organism to produce protein which can be extracted and used.

20

In this instance, the protein produced from the cloned DNA reacts with oxygen or a metabolite of oxygen, such as the superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), hydroxy radical (OH^\cdot), an oxyhalide anion (OCl^- , OBr^- , OI^- , $OSCN^-$), nitric oxide (NO), an organic hydroperoxide or a radical ROO $^\cdot$. The change in light emission enables the
25 oxygen or metabolite(s) to be detected and quantified in live cells, organelles, or on the outer or inner surface of the plasma membrane, or within an organ of a live organism without the need to break them open or the need to separate bound and free fractions. This also enables an enzyme producing oxygen or one of its metabolites, such as chlorophyll, or enzymes such as oxidases and oxygenases which react directly with
30 oxygen or one of its metabolites to attach oxygen to the substrate to be detected and quantified in live cells, organs and whole organisms, or extracts from any one of these.

Also the BOIP can be made *in vitro* by transcription/translation in a cell lysate such as

rabbit reticulocyte lysate or wheat germ extract containing RNA polymerase. The DNA for the BOIP is first engineered to contain an RNA polymerase promoter, such as T7, SP6; bacterial promoter(s), such as lac, ara or trp; or mammalian promoter(s), such as actin, myosin, myelin proteins, TK, MRT-V, SV40, CMV, RSV, metallothionine, antibody, G6P dehydrogenase, and can be amplified *in vitro* using the polymerase chain reaction. A poly-A tail may be added at the 3' end and a tissue specific promoter or enhancer sequence added to the 5' or 3' end of the DNA coding for the BOIP or modified BOIP, enabling it to be expressed specifically in a target cell, such as a myocardial cell or a cancer cell. The expression of the BOIP in the target cell is detected and quantified by light intensity, colour or polarisation, as previously mentioned.

The BOIP, or its DNA or RNA, may be incorporated into a live bacteria or eukaryotic cell using phage, virus, plasmid, calcium phosphate transfection, electroporation, liposome fusion, membrane pore forming proteins, micro-injection or DNA gun. Once inside cells or an appropriate extracellular environment, cell activation or injury will initiate or change the light emission from the BOIP. For example, expression in live organisms by micro-injection of protein, RNA or DNA, or by transgenic manipulation to produce a cell, such as a bacterial, microbial, animal or plant cell, eg a white blood cell, a heart cell, or a yeast, protozoan, fruit fly (*Drosophila*), nematode worm, polychaete worm, fish, human, mouse, rat, sheep, pig, horse or plant, which can generate its own light.

The BOIP can also be incorporated into a defined part of a live cell by chemical means or by genetically engineering the BOIP to contain a signal peptide, which locates the BOIP to the inner or outer surface of the plasma membrane or within a particular organelle, such as peroxisome, mitochondrion, chloroplast, tonoplast, endoplasmic, reticulum, Golgi apparatus, endosome, lysosome, secretory vesicle, nucleus, nucleolus, nuclear membrane, plasma membrane, proteosome, or gap junction, or structure such as membrane receptor ion channel microtubule, cytoskeleton, nuclear skeleton, nuclear receptor, mitotic spindle or microfilaments. The signal peptide, added either chemically or genetically, will normally target the normal or modified BOIP to a particular intra- or extra-cellular site. For example, the sequence MLSRLSLRLLSRYLL or part of cytochrome oxidase on the N-terminus will target the BOIP to the mitochondrion; KKSALLALMYVCPGKADKE

or MLLPVPLLLGLLGLAA at the N-terminus will target the BOIP to the endoplasmic reticulum, a KDEL or HDEL or KEEL sequence at the C-terminus retaining it there. SKL at C-terminus targets BOIP to the peroxisome; PKKKRKV or an extension of this SV40 large T-antigen signal will target it to the nucleus; and a palmitoylation and/or a myristoylation signal will target it to the plasma membrane. By coupling the BOIP to another protein that targets itself to a particular site, the BOIP can also be targeted there. For example, coupling the nuclear proteins nucleoplasmin or lamin B receptor to BOIP targets it to the nucleus; cytochrome oxidase at the N-terminus targets BOIP to the mitochondria; chlorophyll at the N-terminus targets BOIP to the chloroplast; a connexin at the N-terminus targets BOIP to the gap junction or plasma membrane; and SNAP 25 to the plasma membrane.

Other modifications to the apoprotein, BOIP, or nucleotides coding therefor include, but are not limited to:

The apoprotein, such as apopholasin, may also be glycosylated, and used to detect and quantify secretion or movement of proteins through the secretory pathway.

Nucleic acid coding for the BOIP when expressed inside a live cell may not only be modified but also regulated in this cell by gene expression, such as by promoters, enhancers or oncogenes. For example, the apoprotein, such as apopholasin, may be coupled to a gene regulator protein, such as a transcription factor, by genetic or chemical manipulation, such that the movement through a cell or of the regulator protein or its activity, can be detected or quantified.

The BOIP or apoprotein, or its DNA may be linked to another protein or DNA used in therapy, such that the other protein or DNA can be detected in live cells or in a whole organism, *eg* a human.

The apoprotein, such as apopholasin, can also engineered genetically or chemically to contain a site or sites which can be covalently modified by enzymes such as phosphorylation (including ser/thr, his and tyr kinases and phosphatases), transglutamination, proteolysis, ADP ribosylation, gly- or glu-cosylation, halogenation,

oxidation, methylation, palmitoylation, myristylation and farnesylation.

The apoprotein, such as apopholasin, can be engineered genetically or chemically to contain an antigen or intracellular signal binding site, such as Ca^{2+} , cyclic AMP, cyclic GMP, cyclic CMP, IP_3 , IP_4 , diacyl glycerol, ATP, ADP, AMP, GTP, or any oxy- or deoxy-ribonucleoside or nucleotide, a substrate, a drug, a nucleic acid and/or a gene regulator protein.

The BOIP may also be converted to a rainbow protein by engineering a particular site such as described hereinabove into the BOIP, at the N- or C-terminus, or between a chimera of the BOIP and an energy transfer acceptor, such as GFP (wild type or any of the mutant GFPs). This is known as chemiluminescence, bioluminescence or fluorescence resonance transfer (CRET, BRET or FRET, respectively). Conversion of the BOIP to a 'rainbow protein' may be effected by reaction with a cellular substance, modification genetically or chemically, or by linking the BOIP to a fluor, such as the green fluorescent protein or the red fluorescent protein in the deep sea fish *Malacosteus*. The result is a BOIP which changes its colour and/or intensity and/or polarisation of emission. The change in colour occurs by energy transfer, eg resonance transfer (CRET or FRET) or electron transfer.

The initial (unmodified) BOIP may be the apophotoprotein, its DNA or RNA, from the bivalve mollusc *Pholas dactylus*, or it may be another BOIP, such as one from the mollusc *Rocellaria grandis* or the squid *Ommastraphes*, or earthworm luciferase, which produce light with oxygen metabolites in a way very similar to *Pholas dactylus*.

The BOIP, apo-BOIP, or nucleic acid coding for it, whether modified or not, may therefore be used in a range of biology and investigations such as:

- (a) Detection, location and measurement of signals in substrates, such as live cells, organs or organisms, or in extracellular fluids;
- (b) Detection, location and measurement of oxygen and its metabolites in substrates, such as live cells, organs or organisms, or in extracellular fluids, water (sea and fresh), soil or the atmosphere;

- (c) Detection and location of normal cells such as microbes (protozoa, yeast, fungi, moulds, bacteria, viruses);
- (d) Detection and location of abnormal cells, such as cancer cells, hyperactive cells in rheumatoid arthritis and other inflammatory diseases, cells infected with a pathogen, such as a virus or other infectious agents, cells damaged by physical, chemical or biological attack, cells damaged by perfusion or reperfusion injury or cells damaged by oxygen or one of its metabolites;
- (e) Measurement and location of enzymes, particularly those producing oxygen or its metabolites, and other tumour reactions in cells or biological fluids;
- (f) DNA and RNA binding assays;
- (g) Immunoassay and other protein binding assays;
- (h) In genetic engineering, in the development of transgenic animals and plants, and microbes; in horticulture; agriculture; medicine and veterinary medicine; and/or
- (i) in genetic entertainment by incorporation into light sticks, greeting cards or toys to produce light of various colour, intensities, oscillations, flashes and glows; or in comestibles, such as food, drinks, including beers, wines, spirits, colas and other soft drinks.

Accordingly, the present invention further provides an apoprotein, such as pholasin apoprotein (or apopholasin) in both unglycosylated and glycosylated forms, and a BOIP thereof, such as pholasin, either alone (but excluding native proteins *per se* that have already been isolated, such as native pholasin *per se*) or in association with one or more of: a targeting or signal peptide; a glycosylate; a site capable of modification by an enzyme; an antigen or intracellular signal binding site; a promoter, an enhancer or an oncogene or a pharmacologically active substance; or the like. The present invention further provides a recombinant construct comprising a nucleic acid sequence encoding for any of these proteins; a vector containing a nucleic acid sequence encoding for any of these proteins; a host transformed by such vector; a live cell, such as bacterial, insect, eukaryotic, prokaryotic, archae or plant cells containing or expressing any of these proteins; and a rainbow protein, as described herein, together with a nucleic acid sequence encoding therefor.

The present invention will now be illustrated with reference to the following non-limiting examples, in which the methodology referred to is known to those skilled in the art and/or may be carried out by analogy with reference to the protocols disclosed in the following references, the contents of which are herein incorporated by reference in their entirety:

5 BOOKS

1. Campbell,AK. (1988). Chemiluminescence: principles and applications in biology and medicine, pp608. Horwood/VCH, Chichester and Weinheim.
2. Campbell,AK. (1994). Rubicon: the fifth dimension of biology. pp 304. Duckworth, London.

10 PAPERS

1. Campbell,AK Patel,A. (1983) Biochem J. 216:185-194. A homogeneous immunoassay for cyclic nucleotides based on chemiluminescence energy transfer.
2. Roberts,PA Knight,J Campbell,AK. (1987) Anal. Biochem. 160:139-148. Pholasin - a bioluminescent indicator for detecting activation of single neutrophils.
- 15 3. Mueller,T Davies,EV Campbell,AK. (1989) J. Biolum. Chemilum. 3:105-113. Pholasin: Chemiluminescence Detects Mostly Superoxide Anion Released from Activated Human Neutrophils.
4. Mueller,T Campbell,AK. (1989) J. Biolum. Chemilum. 5:25-30. The Chromophore of Pholasin: A Highly Luinescent Protein.
- 20 5. Sala-Newby,G and Campbell,AK (1991) Biochem.J. 279:727-732. Engineering a bioluminescent indicator for cyclic AMP dependent protein kinase .
6. Campbell, AK, Trewavas, AJ and Knight, MR (1996). Calcium imaging shows differential sensitivity to cooling and communication in luminous transgenic plants. Cell Calcium 19: 211-218.
- 25 7. Kendall, JM, Sala-Newby, G Badminton, M, Campbell AK and Rembold, CR (1996). Free Ca^{2+} in the endoplasmic reticulum of living cells measured using aequorin as a pseudo luciferase. Biochem.J 318:383-387
8. Badminton, MN, Campbell, AK and Rembold, CR (1996). J.Biol. Chem. 271:31210-31214. Differential regulation of nuclear and cytosolic Ca^{2+} in HeLa cells.
- 30 9. Sala-Newby, GB, Taylor, KT, Badminton, MN, Rembold, CR and Campbell, AK (1998). Imaging bioluminescent indicators shows Ca^{2+} and ATP permeability thresholds in, live cells attacked by complement. Immunology. 93:4:601-609
- 10.Sala-Newby, GB, Kendall, JM, Jones, H, Taylor, KM, Badminton, MN, Llewellyn, DH and Campbell, AK (1999). Targeting bioluminescent proteins to defined
- 35 compartments fo living cells. Methods in Enzymology Bioluminescence and Chemiluminescence. ed Ziegler, M and Baldwin, T.

EXAMPLE 1: Production of a BOIP in bacteria

c or genomic DNA coding for apopholasin, with or without the cDNA coding for the signal peptide, is amplified by PCR with restriction sites such as BamHI at each end. The cDNA
 5 is run on an agarose gel and the full length DNA eluted and purified. The DNA is then cut with BamHI to generate sticky ends and ligated into an expression plasmid such as pET3a, which has been cut with BamHI also. After ligation the sealed plasmid is transformed into a standard *E.coli* K12 strain such as JM109, a colony picked off for a large plasmid preparation. After checking that the plasmid contains the correct sequence for apopholasin
 10 and is in the correct orientation the plasmid is then used to transform a standard expression strain of *E.coli* such as BL21(DE3) or other expression strain. A colony is picked off the agar plate and grown up for 2h in standard LB broth. IPTG is added as inducer for a further 2h. Apopholasin can then be extracted by breaking the bacteria by lysozyme digestion or sonication in a standard salt medium such as 50mM HEPES pH 7 +/- 1mM ascorbate. Since
 15 the apopholasin is unglycosylated it tends to aggregate and form inclusion bodies. These can be broken using 8M urea or guanidinium chloride and these then dialysed off. If the pH of PAGE gels is alkaline this also tends to allow aggregation of both the unglycosylated and glycosylated apo- and full pholasin. A signal peptide such β -lactamase signal will target the BOIP to the periplasmic space, resulting in the ability to secrete the expressed protein from
 20 the external fluid of the cells.

EXAMPLE 2: Production of a BOIP in insect cells

c or genomic DNA coding for apopholasin is inserted into a plasmid suitable for
 25 conversion into baculovirus when transfected into insect cells. Since pholasin is secreted by *Pholas* itself there is a signal peptide at the N-terminus. Removal of this by PCR will allow cytosolic expression in insect cells. If the signal peptide is left on or changed for honey bee mellitin signal peptide, the apopholasin is secreted into the external medium. The virus containing the DNA for apopholasin is then purified and stored until required.
 30 An aliquot is then added to fresh insect cells and these incubated for 3-7 days. The apopholasin is then isolated from the supernatant if a signal peptide is used, or from the cells if not. The apopholasin can then be purified by ammonium sulphate precipitation, gel filtration and DEAE chromatography. The state of glycosylation can be assessed by

running the protein on PAGE when the molecular weight is 34Kda. Removal of the glycosylation by enzymes returns the protein to the size of apopholasin 23.5Kda. It can be stored frozen or freeze dried, and activated to form pholasin by addition of luciferin as described in Example 3.

5

Since the apopholasin tends to aggregate in the insect supernatant it is important to get the protein into non-aggregating buffer, e.g. 50mM HEPES pH 6, 1-10mM ascorbate, as soon as possible.

10 Formation of pholasin can then be achieved as described in Example 3.

EXAMPLE 3: Generating pholasin and light emission

To generate light the apopholasin must first be converted into pholasin with the luciferin.

15 The luciferin can be extracted from native pholasin by mild acid, or by methanol, mild acid or alkaline treatment of light organs isolated from *Pholas dactylus* or the whole organism. After homogenisation the extract is centrifuged or filtered to remove particulate material. Further purification can be achieved by tlc or hplc. The luciferin is best stored dry, but can be stored at -70°C. The intactness and concentration can be
20 estimated by measuring the absorbance or fluorescence. The details are as follows:

(a) Isolation of the luciferin

Four protocols (1-4) have been developed to extract and isolate the luciferin responsible for light emission in pholasin. The luciferin is a small organic moiety
25 tightly bound to apopholasin when pholasin is isolated from *Pholas dactylus*, but also can be found not bound to apopholasin. Thus the extraction procedure isolates either form of luciferin.

1. The organism *Pholas dactylus* or its light organs are homogenised in 50mM sodium phosphate pH 6.0 on ice. The pholasin is precipitated with saturated ammonium sulphate (4°C stirred), and then removed by
30 centrifugation at *ca* 15,000g for 30min in the cold. The supernatant is then passed down a SEP-PAK silica column, which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The

active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It is dried and stored at -70°C.

2. The organism *Pholas dactylus* or its light organs are homogenised in cold acetone on ice, filtered through a Buchner funnel, and extracted with methanol:acetone (1:1), the residual powder being extracted 3 times with methanol and extracts combined. These are then concentrated in a Rotavaporator and left to stand for 1h on ice to allow further precipitation. The suspension is then refiltered and concentrated. The solution containing the luciferin is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It can be dried and stored at -70°C.
3. The organism *Pholas dactylus* or its light organs are homogenised in cold acetone on ice, and filtered through a Buchner funnel to give an acetone powder. This is then extracted with methanol:acetone (1:1), twice for 10min and then 3 times with methanol. The extracts are combined and concentrated in a Rotavaporator. They are left to stand for 1h on ice to allow further precipitation, refiltered and concentrated. The residual powder is resuspended in 50mM sodium phosphate pH 6.0, 10mM ascorbate, and ultrafiltered with a 10kD Amicon membrane at 4 C for pholasin. The solution containing the luciferin is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It is dried and stored at -70°C.
4. The organism *Pholas dactylus* or its light organs are homogenised in 50mM HEPES buffer, with methanol and 100mM HCl on ice, and

incubated for 2h on ice. After centrifugation at *ca* 15,000g for 30min in the cold, the supernatant is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc with a standard solvent. It is dried and stored at -70°C.

Method 4 normally generates most luciferin. The luciferin is characterised by its absorbance and fluorescence spectrum, and by its chemiluminescence with DMSO, NaOCl and apopholasin.

(b) *Generation of pholasin from apopholasin and the luciferin*

A small sample of the luciferin (1-10µl) is added to apopholasin in an appropriate buffer (50mM HEPES pH 6-7.5, +/- 0.1% gelatine, +/- 1-10mM ascorbate, or 500mM NaCl, 10mM TES, 1mM EDTA, 1mM mercaptoethanol pH 6-7.5). The mixture is incubated at room temperature for up to 24h, and the pholasin assayed by adding an oxygen metabolite, e.g. NaOCl, or luciferase to a sample. When apopholasin has been expressed in cells, the luciferin is added externally, microinjected into individual cells or added via liposomes to get the luciferin into the cell.

Light is detected and quantified in a standard luminometer, imaging camera (intensified or CCD), or by a silicon chip.

EXAMPLE 4: Production of a BOIP in vitro

c or genomic DNA coding for apopholasin, with or without the signal peptide, is amplified by PCR with the 5' primer containing the DNA coding for T7 RNA polymerase. The DNA product is purified and precipitated. After dissolving in 10mM tris/1mMEDTA pH7, the DNA is added to a standard *in vitro* transcription/translation system such as rabbit reticulocyte lysate or wheat germ agglutinin and incubated at 30°C for 30-60min. The apopholasin can then be purified and activated to form pholasin as described in Example 3.

EXAMPLE 5: Targeting a BOIP in vitro

The BOIP can also be incorporated into a defined part of a live cell by chemical means or by genetically engineering the BOIP to contain a signal peptide which locates the BOIP to the inner or outer surface of the plasma membrane or within a particular organelle such as peroxisome, mitochondrion, chloroplast, tonoplast, endoplasmic reticulum, Golgi, endosome, lysosome, secretory vesicle, nucleus, nucleolus, proteosome, or gap junction, or structure such as microtubule, cytoskeleton, nuclear skeleton, nuclear receptor, or mitotic spindle. The signal peptide, added either chemically or genetically, will normally target the normal or altered BOIP to a particular intra- or extra-cellular site for example, the sequence MLSRLSLRLLSRYLL or part of cytochrome oxidase on the N-terminus will target the BOIP to the mitochondrion; KKSALLALMYVCPGKADKE or MLLPVPLLLGLLGLAA or the ER protein calreticulin at the N-terminus will target the BOIP to the endoplasmic reticulum, a KDEL or HDEL sequence at the C-terminus retaining it there. SKL at C-terminus targets BOIP to the peroxisome, PKKKRKV or an extension of this SV40 large T-antigen signal will target it to the nucleus, and a palmitoylation and/or a myristoylation signal (MGCVCSSNPD = the LCK N-terminal acylation motif from tyrosine kinase) will target it to the plasma membrane. By coupling the BOIP to another protein which targets itself to a particular site then the BOIP is also targeted here. For example, coupling the nuclear proteins nucleoplasmin or lamin B receptor to BOIP targets it to the nucleus; cytochrome oxidase at the N-terminus targets BOIP to the mitochondria; chlorophyll at the N-terminus targets BOIP to the chloroplast; and a connexin at the N-terminus targets BOIP to the gap junction or plasma membrane, SNAP 25 to the plasma membrane.

In order to target pholasin to defined sites in living cells, the DNA coding for these targeting sequences are added by using PCR. For cytosolic apopholasin the native signal peptide is removed and also the BOIP can be linked to larger proteins at the N- or C-terminus such as firefly luciferase or aequorin to prevent it getting into the nucleus. This also enables ATP and oxygen metabolites, or Ca^{2+} and oxygen metabolites to be measured simultaneously in the same cells by intensity, colour or polarisation of the different bioluminescent indicators. A multiple bioluminescent indicator can also be engineered by PCR, or by using restriction enzyme sites, from the DNA coding for 3 or more

bioluminescent proteins. A simple screen of the transformed bacteria enables the multiple rainbow protein to be isolated with 2-3 colours or more.

The DNA is then added to an *in vitro* transcription/translation system as described in Example 4 in the presence of the organelle to be targeted (e.g. microsomes for the endoplasmic reticulum, which glycosylate apopholasin).

The new DNA can also be inserted into a plasmid by standard techniques, and transformed into bacteria or transfected or injected into eukaryotic cells such as HeLa or COS.

Addition of the luciferin as described in Example 3 allows formation of pholasin which can then be detected by light emission. Changes in oxygen metabolite production are then be detected by a luminometer or imaging camera when the cells are exposed to external oxygen metabolites, a change in oxygen concentration, addition of stimuli e.g. TNF, EGF, hormones or drugs, or attack by pathogens such as bacteria, viruses, complement, antibodies, toxins, and cells of the immune system.

EXAMPLE 6: Engineering a covalent modification site into a BOIP

- (a) The site coding a protein kinase A (RRAS or kemptide), protein kinase C (MARCKS), MAP kinase, ERK, the ER - nuclear signalling kinase IRE1P or a phosphatase is added to the N- or C-terminus or inserted at various sites within the apopholasin by PCR and expressed as described in Examples 1-5. Pholasin is then generated by addition of the luciferin as described in Example 3.

Addition of the catalytic subunit for protein kinase A, or activation via cyclic AMP inside cells, leads to phosphorylation or dephosphorylation of the modified pholasin and change in light emission (intensity, colour or polarisation).

A preliminary screen is necessary to select the appropriate proteins and to discard any which have lost all activity.

- (b) The site coding a protease (thrombin, enterokinase, HIV protease, caspase) is added to the N- or C-terminus of the apopholasin by PCR or inserted at various sites within the protein, and expressed as described in Examples 1-5. Pholasin is then generated by addition of the luciferin as described in Example 3.

5

EXAMPLE 7: Engineering a BOIP into a "Rainbow Protein"

cDNA coding for apopholasin is linked to another protein by using the cDNA coding for that protein. For example, wild type GFP, the S65T mutant of the green fluorescent protein, YGFP, or EGFP are linked to apopholasin by PCR at the N- or C-terminus, or by splitting one or both proteins using multi-step PCR. In between there is a 'reactive' peptide with a protease site (α thrombin or enterokinase) and a binding site for IP_3 , or the 15 amino acid sequence form IP_3 kinase (an IP_4 binding site). At the C-terminus of the GFP, a peptide containing 6 lysine residues may also be added via PCR. The protein is expressed and fluorescein covalently linked to these lysines by addition of fluorescein isothiocyanate. Addition of the luciferin forms pholasin as described in Example 3. The change in colour occurs by chemiluminescence resonance energy transfer. Without fluorescein the rainbow protein emits blue-green light (508nm), which changes to blue (490nm) when the reactive substance binds to the reactive peptide, or when either thrombin or enterokinase is added. When the 6 amino acid linker is used the colour starts as green (530nm), and will then change from green, to blue-green and then blue as the particular reactive sequence binds their respective analytes. Use of rhodamine instead of fluorescein generates a rainbow protein which changes from red to green to blue.

- 25 A preliminary screen is necessary to select the appropriate rainbow proteins and to discard any which have lost all activity.

The other protein linked to apopholasin may be, for example, any one of the following linked chemically or genetically:

30

1. Firefly or any benzothiazole luciferase to the N or C terminus gives two colours for ATP and oxygen metabolites.

2. Any imidazolopyrazine luciferase, including coelenterazine systems - decapod shrimp, fish, squid, *Renilla*, anthozoan, Chaetognate, radiolarian, or copepod and *Vargula* systems - ostracod, *Porichthys* and similar fish, cypridinids and *Vargula*.
3. Any tetrapyrrole luciferase such as dinoflagellate, euphausiid or stomiatoid fish.
- 5 4. Bacterial luciferase and other aldehyde or flavin luciferases, including polychate worm.
5. Any GFP, including wild type, S65T, enhanced GFP, blue GFP, yellow GFP, *Renilla* GFP, *Ptilocarpus* GFP, and *Pennatula* GFP, any anthozoan GFP, or any coelenterate GFP.
- 10 6. The red fluorescent proteins from stomiatoid fish - *Malactosteus*, *Aristostomias*, *Photostomias*.
7. The phycobiliproteins - phycoerythrin and phycocyanobilin.
8. The blue fluorescent lumazine protein in the bacterium *Photobacterium*.
9. The yellow flavin fluorescent protein in *Vibrio*.
- 15 10. Any lysine or arginine or other amino acid side chain where a fluor can be added covalently. In which the case the rainbow protein may emit more than two colours. For example, rhodamine on a pholasin-linker-GFP chimera will turn from red to green to blue.
- 20 A preliminary screen may be necessary to select chimeras which have not lost all bioluminescent activity.

The 'reactive' peptide may be a binding site for any analyte, protein or DNA, metabolite, substrate vitamin, an enzyme such as protein kinase C or phosphatase, ion channel, ion pump, antigen, antibody, nucleotide or nucleoside such as ATP, GTP, ADP, AMP, adenosine, cAMP, cCMP, cCCP or their deoxy equivalents, and inositol phosphates such as IP₃ or IP₄, a lipid such as diacyl glycerol, phosphatidyl inositol bisphosphate, phosphate, a cation such as Ca²⁺, K⁺ or Na⁺, Cu²⁺ or Zn²⁺, or anion such as Cl⁻, sulphate, or gas such as NO, O₂ or H₂, or a protein binding site such as calmodulin, kinesin, dynein, tubulin, or myosin.

When pholasin is triggered by oxygen metabolites, the *Pholas* luciferase or peroxidase, energy transfer occurs from pholasin oxyluciferin through GFP to fluorescein resulting in

a yellow emission. Addition of thrombin for 3h cleaves the GFP-fluorescein from the pholasin and the light emission returns to the blue of native pholasin. Addition of IP_3 to the full chimera alters the efficiency of energy transfer. As a result there is a change in the ratio of light emitted in the yellow to blue. This ratio is directly related and can be plotted against the concentration or amount of analyte. The light is detected in a dual wavelength luminometer or ratiometric imaging camera and the ratio of blue to green light measured.

Alternatively any fluors can be used, and any binding sites with the right characteristics as shown in these examples will work provided a simple screen is used to select the right chimeras.

EXAMPLE 8: Engineering a BOIP into a "Rainbow Protein" for two analytes together

Apopholasin is linked to firefly luciferase by using cDNAs and PCR, followed by expression in insect cells as described in Example 2. Addition of the luciferin as described in Example 3 generates the pholasin. In the presence of firefly luciferin (1mM), ATP and oxygen metabolites, this chimera emits blue and yellow simultaneously which can be independently measured by using a dual wavelength luminometer or imaging camera.

EXAMPLE 9: Expression of BOIPs in mammalian cells

Apopholasin, c or genomic, in an expression plasmid with the CMV promoter, is transfected into HeLa cells. After incubation for 3 days to allow expression of the apopholasin, the luciferin is added to form pholasin. Expression is checked using a polyclonal antibody to pholasin raised in rabbits. Addition of oxygen metabolites outside the cell allows the permeability of the plasma membrane to oxygen metabolites to be assessed. As the oxygen metabolites permeate into the cytosol, the light emission increases.

EXAMPLE 10: Expression of BOIPs in plants

c or genomic DNA coding for apopholasin is inserted into a plasmid with the cauliflower mosaic virus promoter and transformed into *Agrobacterium tumefaciens*. These are then added to a tobacco leaf, seedlings generated, and those expressing apopholasin selected. The plants are grown to seed, and seedlings grown from this seed. Addition of luciferin forms the pholasin as described in Example 3. Stressing the plant, e.g. with wind, touch, cold, or peroxide, or during growth and development or by a hormone, generates light, showing the formation of oxygen metabolites within the live plant. A cell-specific promoter engineered on to the apopholasin cDNA before making the transgenic plant enables oxygen metabolites to be detected in specific cells within the whole, living plant.

EXAMPLE 11: Detection of oxidative damage in vitro

Addition of pholasin to serum or plasma from a rat, mouse or human enables oxygen metabolites to be detected and measured on addition of a drug or other substance of interest.

EXAMPLE 12: Detection of ROMs in a heart cells

Reperfusion has been proposed to lead to oxygen metabolite damage in cardiac myocytes. Pholasin allows this to be tested for the first time. Plasmid containing apopholasin cDNA and the CMV promoter is transfected into isolated cardiac myocytes in culture. Expression occurs within 1-3 days, and pholasin is formed by addition of the luciferin as described in Example 3. Subjecting the cells to hypoxia followed by readmission of normal oxygen leads to light emission, showing that oxygen metabolites have been generated inside the cells. By using an imaging camera, the digital or analogue nature of this can be assessed as the number of cells emitting light can be visualised and counted.

EXAMPLE 13: Detection of ROMs in the nucleus and endoplasmic reticulum (ER)

Plasmid-containing apopholasin cDNA with either nucleoplasmin DNA or calreticulin DNA (with or without KDEL on the C-terminus) linked to the pholasin DNA, to target the apopholasin to the nucleus or ER respectively, and the CMV promoter for expression, is transfected into HeLa cells in culture. Expression occurs within 1-3 days, and pholasin is formed by addition of the luciferin as described in Example 3. Addition of oxygen metabolites outside the cells, or hypoxic/oxygen shock generates light measured in a luminometer, showing how fast oxygen metabolites penetrate into these organelles. By imaging with a photon counting imaging camera, the number of cells permeable to oxygen metabolites can be counted. Location of the pholasin can be assessed by imaging live cells, or by using immunofluorescence with the pholasin antibody on partially-fixed cells or GFP-pholasin in live cells. Using a rainbow protein, two or more analytes can be detected together.

EXAMPLE 14: Use of pholasin as a protein label

Pholasin can be used as a label in homogeneous or heterogeneous immunoassay. Apopholasin is first covalently linked to an antibody to HIV, and pholasin formed by addition of luciferin as described in Example 3. The antibody is then used in a standard chemiluminometric immunoassay format. Addition of HIV antigen leads to an increase in antibody binding and an increase in light emission dependent on the amount of HIV added. The amount of HIV in a blood sample can be assessed by relating the pholasin light emission in the sample to the standard curve.

EXAMPLE 15: Pholasin as a DNA label

Apopholasin is covalently linked to an oligonucleotide probe for detecting the presence of the cystic fibrosis gene. Addition of the probe to DNA in a standard Southern blot allows the probe to bind when the gene is present. Addition of luciferin as described in Example 3 allows the pholasin to form. Addition of hypochlorite (10mM) in barbitone buffer pH 9 causes the pholasin to flash and the gene can be visualised by the photon counting imaging camera.

EXAMPLE 16: Pholasin in a two hybrid system

Protein-protein interaction can be detected by engineering apopholasin to one half of a
 5 two hybrid system and GFP to the other. Binding will allow the yeast to grow.

EXAMPLE 17: Pholasin in genetic entertainment

Pholasin is able to chemiluminesce at a wide range of pH (3-10), including acid pH such
 10 as 3-4. Thus it can be added to drinks such as beer, cola, soft drinks, and spirits to make
 them glow. It can also make food glow by adding to them to the ingredients of cakes,
 icing, popcorn; by painting the pholasin or apopholasin on to the food, or by making it
 genetically in the source of the food. It can be used in a wide range of toys and other
 entertaining devices including squirt guns, greeting cards, pens.

15 The rainbow proteins can also be used as an alternative to pholasin alone, resulting in a
 rainbow of colours and colour changes.

EXAMPLE 18: Pholasin in transgenic animals

20 Transgenic animals such as nematodes, mice or plants can be generated from apopholasin
 cDNA by standard techniques. Injecting the luciferin or incubating whole plant in it forms
 the active pholasin. Oxygen or its metabolites can then be detected, measured and imaged,
 in an intact organ, or from the whole organism. It can also be used in humans, in DNA
 25 therapy or diagnosis.

EXAMPLE 19: Apoprotein from the luminous squid *Ommastrophes*

The use of apoprotein from the luminous squid *Ommastrophes* is substituted for
 30 apopholasin, and the methods of Examples 1 to 18, above, are carried out.

EXAMPLE 20: Apoprotein from the mollusc *Rocellaria*

The use of the apoprotein from the mollusc *Rocellaria* is substituted for apopholasin, and the methods of Examples 1 to 18, above, are carried out.

EXAMPLE 21: Earthworm luciferase

5

The use of earthworm luciferase as a BOIP is substituted for apopholasin, and the methods of Examples 1 to 18, above, are carried out.

10 **EXAMPLE 22**

Genomic DNA from *Pholas*, *Rocellaria*, *Ommastrophes*, or earthworm is substituted for the recombinant protein in Examples 1 to 18, above, the methods of which are carried out in an analogous manner.

69314-0304
T.D. 247860

1. An isolated, purified or recombinant nucleic acid sequence comprising:
- (a) a sequence that encodes the apophotoprotein of pholasin (alternatively,
5 'apopholasin');
- (b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or
- (c) a sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or
- 10 (d) an oligonucleotide specific for any of the sequences (a), (b) or (c)
- PROVIDED THAT such homologous sequences according to (b) or (c) encode a protein capable of binding to luciferin.
2. A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in Figure 4B.
- 15 3. A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in any one of Figures 1, 2, 3, 4A, 6 or 9.
4. A sequence according to any preceding claim, wherein the apopholasin is non-glycosylated.
5. A sequence according to any preceding claim, wherein the apopholasin is
20 glycosylated.
6. An isolated, purified or recombinant construct incorporating a sequence encoding an apophotoprotein whose expression in a substrate, in association with a luciferin therefor, signals the presence of oxygen or an oxygen metabolite in the substrate.
7. An isolated, purified or recombinant construct incorporating a sequence encoding
25 an apophotoprotein whose expression in a substrate, in association with a luciferin therefor, signals the presence of oxygen or an oxygen metabolite in the absence of a corresponding luciferase in the substrate.
8. A construct according to claim 6 or claim 7, wherein the apophotoprotein is apopholasin.
- 30 9. A recombinant construct according to any one of claims 1 to 8, wherein the nucleic acid sequence is linked operably with nucleotides enabling expression and secretion of the apopholasin in a cellular host.
10. DNA or RNA according to any of claims 1 to 9.

11. An isolated, purified or recombinant polypeptide comprising apophotoprot
pholasin (apopholasin), or a mutant or variant thereof, which mutant or variant is capable
of binding to luciferin.
12. An isolated, purified or recombinant polypeptide according to claim 11
5 comprising the amino acid sequence of Figure 4 or Figure 5.
13. The apopholasin according to claim 11 or claim 12 when expressed by
recombinant DNA or RNA according to claim 10.
14. The apopholasin according to claim 13, which is non-glycosylated.
15. A cell, plasmid, virus or live organism having incorporated expressibly therein a
10 sequence according to any one of claims 1 to 10, whereby it is capable of producing an
apoprotein.
16. A vector comprising a sequence according to any one of claims 1 to 10.
17. A host cell transformed or transfected with a vector according to claim 16.
18. A bioluminescent oxidative indicator protein (BOIP), comprising an
15 apophotoprotein according to any one of claims 11 to 14 in association with a luciferin.
19. A BOIP according to claim 18, wherein the luciferin is derived from *Pholas
dactylus*.
20. A method for the preparation of a bioluminescent oxidative indicator protein
20 (BOIP), which method comprises bringing an apophotoprotein into association with a
luciferin therefor.
21. A method for the detection and/or measurement of oxygen or one of its
metabolites extracellularly, which method comprises providing a bioluminescent
oxidative indicator protein (BOIP) extracellularly and thereafter detecting and/or
quantifying light emission therefrom and/or changes in colour, intensity and/or
25 polarisation of emission(s), wherein the apophotoprotein comprises recombinant
apopholasin.
22. A method for the detection and/or measurement of oxygen or one of its
metabolites in live cells (intracellularly), which method comprises providing a BOIP
intracellularly and thereafter detecting and/or quantifying light emission therefrom and/or
30 changes in colour, intensity and/or polarisation of emission(s) therefrom.
23. A method according to claim 21 or 22, wherein said BOIP is selected from native
or chemically- or genetically- modified BOIP or a 'rainbow protein' based on such a
BOIP.

24. A method according to any one of claims 21 to 23, wherein said BOIP includes a signal peptide, targetting it to a pre-determined extra- or intra- cellular site.
25. A method according to any one of claims 21 to 23, comprising incubating a test sample with a cell according to claim 15 or with a membrane preparation derived therefrom.
26. A method according to any one of claims 21 to 24, wherein light emission takes place in the absence of a luciferase.
27. The use of a sequence or a protein according to any one of claims 1 to 19 in the detection, diagnosis or measurement of oxygen or a metabolite thereof.
- 10 28. A diagnostic kit incorporating a sequence or protein according to any one of claims 1 to 19.
29. A method for obtaining a substantially homologous source of apopholasin, which method comprises culturing cells having incorporated expressibly therein a polynucleotide encoding apopholasin as defined in any one of claims 1 to 10, and
15 thereafter recovering the cultured cells.
30. A method, use or kit according to any one of claims 20 to 29, substantially as hereinbefore described with particular reference to the Examples.

0031142.050704

Clone 40:

GAATTCGGCAGAGTCGGAAAAGAACAATAATGGCTTGTATCGTTTTTCGTT
 GCTCTTGTGCTCTATGCTTAATGCAACCGGGTTCCGGTGAGGAAGTACA
 ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
 GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA
 GATCGGGCTTTGGGGCTGTGTGGATTGAACGGGCGGGCCAGGTACCAC
 AAAAGCCGTCTGGATTAACGGAGTAACGACACGCAGTCATGTGTAACAA
 GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
 TACAGACCACAGGAAGACGGAACTGAGAAAACCTTTACAAGAAAATTCTC
 TAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGG
 ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
 TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGAT
 TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
 AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA
 GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT
 CTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC
 AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG
 ATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAAAA
 AAAAAAAAAAAAACTCGAG

Clone 3:

GAATTCGGCAGAGGGAAAAGAACAATAATGGCTTGTATCGTTTTTCGTT
 GCTCTTGTGCTCTATGCTTAATGCAACCGGGTTCCGGTGAGGAAGTACA
 ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
 GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAG
 GATCGGGCTTTGGGGCTGTGTGGATTGAACGGGCGGGCCAGGTACCAC
 AAAAGCCGTCTGGATTAACGGAGTAACGACACGCAGTCATGTGTAACAA
 GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
 TACAGACCACAGGAAGACGGAACTGAGAAAACCTTTACAAGAAAATTCTC
 TAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGG
 ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
 TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTTAT
 TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
 AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA
 GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT
 CTGGTAGATCTATCAGACCCTTTTATCAGCAGGACAACCTGGTCGTTACC
 AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG
 ATAGAATATTGAAAATAA

Clone 5:

GTCGAAAAGAACAATAATGGCTTGTATCGTTTTTCGTTGCTCTTGTGCTCTATGCTTAATGCAACCGGG
 TTCCGGTGAGGAAGTACAATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACTG
 GATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAGGATCGGGCTTTGGGGCTGTG
 TCGGATTGAACGGGCGGGCCAGGTACCACAAAAGCCGTCTGGATTAACGGAGTAACGACACGCAGTC
 ATGTGTAACAAGAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGACTACAGACC
 ACAGGAAGACGGAACCTGAGAAAACCTTTACAAGAAAATTCTCTAGCAAAATGCCAGGCACTTACATGCT
 TATGGACGTGTGCGCTACAAGGGACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAG
 GGTGTCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTTATTCCATCTGAGACAAT
 CGAGGATGATATCAAGGACTGTGGGCTCTTAGACCAAGATGTTGAACTCGATTATACGTGGACTCAAAA
 CGAGTGTGATCTACCAGACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTTCTG
 GTAGATCTATCAGACCCTTTTATCAGCAGGACAACCTGGTCGTTACCAGACACCTATAACGTGTCCTCA
 TCAATAATGTGTAAAACAGAAATAATCGATAGAATATTGAAAATAAAATGTTAATAGACACTGGTTGAA
 AAAAAAAAAAAAACTCGAG

Fig. 1

clone 40 GAATTCGGCACGAGTCGGAAAAGAACAATAATGGCTTGTATCGTTTTTCGTT
clone 3 GAATTCGGCACGAG--GGAAAAGAACAATAATGGCTTGTATCGTTTTTCGTT
clone 5 -----GTCGGAAAAGAACAATAATGGCTTGTATCGTTTTTCGTT
* *****

clone 40 GCTCTTGTGCTCTATGCTTAATGCAACCGGGTTCCGGTGAGGAAGTACA
clone 3 GCTCTTGTGCTCTATGCTTAATGCAACCGGGTTCCGGTGAGGAAGTACA
clone 5 GCTCTTGTGCTCTATGCTTAATGCAACCGGGTTCCGGTGAGGAAGTACA

clone 40 ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
clone 3 ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
clone 5 ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT

clone 40 GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA
clone 3 GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAG
clone 5 GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAG

clone 40 GATCGGGCTTTGGGGCTGTGTGCGATTGAACGGGCGGGCCAGGTACCAC
clone 3 GATCGGGCTTTGGGGCTGTGTGCGATTGAACGGGCGGGCCAGGTACCAC
clone 5 GATCGGGCTTTGGGGCTGTGTGCGATTGAACGGGCGGGCCAGGTACCAC

clone 40 AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA
clone 3 AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA
clone 5 AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA

clone 40 GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
clone 3 GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
clone 5 GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC

clone 40 TACAGACCACAGGAAGACGGAAGTGAAGAACTTTTACAAGAAATTTCTC
clone 3 TACAGACCACAGGAAGACGGAAGTGAAGAACTTTTACAAGAAATTTCTC
clone 5 TACAGACCACAGGAAGACGGAAGTGAAGAACTTTTACAAGAAATTTCTC

clone 40 TAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGG
clone 3 TAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGG
clone 5 TAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGG

clone 40 ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
clone 3 ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
clone 5 ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG

clone 40 TCCCTATATGACGAAGATAACAATGGTGTAATGGATGAAGGTAAGGTGAT
clone 3 TCCCTATATGACGAAGATAACAATGGTGTAATGGATGAAGGTAAGGTGAT
clone 5 TCCCTATATGACGAAGATAACAATGGTGTAATGGATGAAGGTAAGGTGAT

clone 40 TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
clone 3 TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
clone 5 TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC

Fig. 2 (Part 1 of 2)

clone 40 AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA
clone 3 AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA
clone 5 AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA

clone 40 GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT
clone 3 GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT
clone 5 GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT

clone 40 CTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACTGGTCGTTACC
clone 3 CTGGTAGATCTATCAGACCCTTTTATCAGCAGGACAACTGGTCGTTACC
clone 5 CTGGTAGATCTATCAGACCCTTTTATCAGCAGGACAACTGGTCGTTACC

clone 40 AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG
clone 3 AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG
clone 5 AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG

clone 40 ATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAAAA
clone 3 ATAGAATATTGAAAATAA-----
clone 5 ATAGAATATTGAAAATAAAATGTTAATAGACACTGGTTGAAA-----AAA

clone 40 AAAAAAAAAAAAACTCGAG
clone 3 -----
clone 5 AAAAAAAAAAAAACTCGAG

Fig. 2 (Part 2 of 2)

Untranslated region

GAATTCGGCACGAGTCGGAAAAGAACAAA

Translated region

ATG GCT TGT ATC GTT TTC GTT GCT CTT GTC GCT CTA TGC TTA ATG	45
M A C I V F V A L V A L C L M	
CAA CCG GGT TCC GGT GAG GAA GTA CAA TGC GCG ATG AAT TGG ACA	90
Q P G S G E E V Q C A M N W T	
CAA GCT AAT GAA TAT GTG TTC AAC GTG GAC TGG ATG ACC ATT TTC	135
Q A N E Y V F N V D W M T I F	
ATC TAC GAC TAT GGC GCT CAA GAG CAA CTG TAC GAA GAT CGG GCT	180
I Y D Y G A Q E Q L Y E D R A	
TTG GGG CTG TGT CGG ATT GAA CGG GCC GGC CCA GGT ACC ACA AAA	225
L G L C R I E R A G P G T T K	
GCC GTC TGG ATT AAC TGG AGT AAC GAC ACG CAG TCA TGT GTA ACA	270
A V W I N W S N D T Q S C V T	
AGA AAA ACA ATC TTC TTC GAG GTT GGT GGA GAA ATT GCC CGG CTA	315
R K T I F F E V G G E I A R L	
GTT GAC TAC AGA CCA CAG GAA GAC GGA ACT GAG AAA ACT TTT ACA	360
V D Y R P Q E D G T E K T F T	
AGA AAA TTC TCT AGC AAA ATG CCA GGC ACT TAC ATG CTT ATG GAC	405
R K F S S K M P G T Y M L M D	
GTG TGC GCT ACA AGG GAC GCT GAT GAT AAA TGC ATC GAA GGC ACA	450
V C A T R D A D D K C I E G T	
ATT GTG GTG ACA GTC AGG GTG TCC CTA TAT GAC GAA GAT AAC AAT	495
I V V T V R V S L Y D E D N N	
GGT GTA ATG GAT GAA GGT AAG GTG ATT CCA TCT GAG ACA ATC GAG	540
G V M D E G K V I P S E T I E	
GAT GAT ATC AAG GAC TGT GGG CTC TTA GAC CAA GAT GTT GAA CTC	585
D D I K D C G L L D Q D V E L	
GAT TAT ACG TGG ACT CAA AAC GAG TGT GAT CTA CCA GAC ACA GTA	630
D Y T W T Q N E C D L P D T V	
GAC GAG GCT GAA GAC ACA CCG TCA GAA ACT GGA GAA TTC TTC TGG	675
D E A E D T P S E T G E F F W	
TAG ATC TAT CAG ACT ACT TTT ATC AGC AGG ACA ACT GGT CGT TAC	720
*	
CAG ACA CCT ATA ACG TGT CCT CAT CAA TAA	750

* = stop for translation

Fig. 4A

SUBSTITUTE SHEET (RULE 26)

EcoR I

GAATTCGGCACGAGTCGGAAAAGAACAAA

ATG GCT TGT ATC GTT TTC GTT GCT CTT GTC GCT CTA
TGC TTA ATG CAA CCG GGT TCC GGT GAG GAA GTA CAA
TGC GCG ATG AAT TGG ACA CAA GCT AAT GAA TAT GTG
TTC AAC GTG GAC TGG ATG ACC ATT TTC ATC TAC GAC
TAT GGC GCT CAA GAG CAA CTG TAC GAA GAT CGG GCT
TTG GGG CTG TGT CGG ATT GAA CGG GCC GGC CCA GGT
ACC ACA AAA GCC GTC TGG ATT AAC TGG AGT AAC GAC
ACG CAG TCA TGT GTA ACA AGA AAA ACA ATC TTC TTC
GAG GTT GGT GGA GAA ATT GCC CGG CTA GTT GAC TAC
AGA CCA CAG GAA GAC GGA ACT GAG AAA ACT TTT ACA
AGA AAA TTC TCT AGC AAA ATG CCA GGC ACT TAC ATG
CTT ATG GAC GTG TGC GCT ACA AGG GAC GCT GAT GAT
AAA TGC ATC GAA GGC ACA ATT GTG GTG ACA GTC AGG
GTG TCC CTA TAT GAC GAA GAT AAC AAT GGT GTA ATG
GAT GAA GGT AAG GTG ATT CCA TCT GAG ACA ATC GAG
GAT GAT ATC AAG GAC TGT GGG CTC TTA GAC CAA GAT
GTT GAA CTC GAT TAT ACG TGG ACT CAA AAC GAG TGT
GAT CTA CCA GAC ACA GTA GAC GAG GCT GAA GAC ACA
CCG TCA GAA ACT GGA GAA TTC TTC TGG TAG

ATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACCAGAC
ACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCGA
TAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAA
AAAAAAAAAAAAAAAAACTCGAG

Xho I

Fig. 4B

EEVQCAMNWTQANEYVFNVDMTIFIYDYGAQEQLYEDRALGLCRIERAGPGTTKAV
WINWSNDTQSCVTRKTIFFEVGGEIARLVDIRPQEDGTEKTFTTRKFSSKMPGTYYLM
DVCATRDADDKCIEGTIVVTVRVSLYDEDNNGVMDEGKVIPSETIEDDIKDCGLLDQ
DVELDYTWTQNECDLPDTVDEAEDTPSETGEFFW

Fig. 5A

MACIVFVALVALCLMQPGSGEEVQCAMNWTQANEYVFNVDMTIFIYDYGAQEQLYE
DRALGLCRIERAGPGTTKAVWINWSNDTQSCVTRKTIFFEVGGEIARLVDIRPQEDG
TEKTFTTRKFSSKMPGTYYLMDVCATRDADDKCIEGTIVVTVRVSLYDEDNNGVMDEG
KVIPSETIEDDIKDCGLLDQDVELDYTWTQNECDLPDTVDEAEDTPSETGEFFW

Fig. 5B

clone 40
BioXAct
rTth
GAATTCGGCAGAGTCGGAAAAGAACAAAATGGCTTGTATCGTTTTCGTT
TGGCTTGTATCGTTTTCGTT

clone 40
BioXAct
rTth
GCTCTTGTGCTCTATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACA
GCTCTTGTGCTCTATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACA
TATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACA

clone 40
BioXAct
rTth
ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT

clone 40
BioXAct
rTth
GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA
GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA
GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA

clone 40
BioXAct
rTth
GATCGGGCTTTGGGGCTGTGTGCGGATTGAACGGGCGGGCCAGGTACCAC
GATCGGGCTTTGGGGCTGTGTGCGGATTGAACGGGCGGGCCAGGTACCAC
GATCGGGCTTTGGGGCTGTGTGCGGATTGAACGGGCGGGCCAGGTACCAC

clone 40
BioXAct
rTth
AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA
AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA
AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA

clone 40
BioXAct
rTth
GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC

clone 40
BioXAct
rTth
TACAGACCACAGGAAGACGGAAGTGAAGAACTTTTACAAGAAATTCCTC
TACAGACCACAGGAAGACGGAAGTGAAGAACTTTTACAAGAAATTCCTC
TACAGACCACAGGAAGACGGAAGTGAAGAACTTTTACAAGAAATTCCTC

clone 40
BioXAct
rTth
TAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGG
TAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGG
TAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGG

clone 40
BioXAct
rTth
ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG

clone 40
BioXAct
rTth
TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGAT
TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGAT
TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGAT

clone 40
BioXAct
TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC

Fig. 6 (Part 1 of 2)

09831142-05001

rTth	TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC *****
clone 40 BioXAct rTth	AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA *****
clone 40 BioXAct rTth	GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT *****
clone 40 BioXAct rTth	CTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC CTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC CTGGTANATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC *****
clone 40 BioXAct rTth	AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAAC *****
clone 40 BioXAct rTth	ATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAAAA ATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAA
clone 40 BioXAct rTth	AAAAAAAAAAAAAACTCGAG

Fig. 6 (Part 2 of 2)

Oligo 1

ACI ATH TTY TTY CAR GT

Oligo 2

CAR GAR GAR GGN ACI GA

Oligo 2A

TCI GTN CCY TCY TCY TG

Oligo N

TTY AAY GTI GAY TGG ATG

M=A/C

R=A/G

W=A/T

S=G/C

Y=C/T

K=G/T

V=A/C/G

H=A/C/T

D=A/G/T

B=C/G/T

N=A/C/G/T

I=inosine

Oligo 3A

ACA CAG CCC CAA AGC CCG AT

Oligo 4S

.TTG CCC GGC TAG TTG ACT AC

Oligo 5A

CAT ATT TCA ACC AGT GTT TAT TAA

Oligo 6A

CAA TTG TGC CTT CGA TGC A

Oligo 7S

GGA CTG TGG GCT CTT AG

Oligo 8S

ATG GCT TGT ATC GTT TTC GT

Oligo T7

Fig. 7A

Fig. 7B

Oligo ExS

CCA CAC GGA TCC TGA GGA AGT ACA ATG

Oligo ExA

CCA CAC GGA TCC TTA TTG ATG AGG ACA

Oligo Bac1

CTT GTT TTT ATG GTC GTC TAC ATT TCT TAC ATC TAT GCG GAG
GAA GTA CAA TG

Oligo C9 12

CCA CAC AGA TCT AGA ATG AAA TTC TTA GTC AAC GTT GCC CTT
GTT TTT ATG GTC

Oligo BV5

TTT ACT GTT TTC GTA ACA GTT TTG


Oligo BV3

CAA CAA CGC ACA GAA TCT AG

Fig. 7C

AccI		630				
AflIII		405		734		
AluI 95						
AlwNI	659					
Asp 718		215				
AsuI		204	209			
BanI		215				
BanII		564				
BcnI		51	310			
BglIII		678				
BspI 286		564				
BstNI		213		384		
BstUI	77					
CfrI0I	206					
CfrI3I	204		209			
DdeI		345		528		565
DpnI		174		615		680
EcoRI	665					
EcoRII	211		382			
EcoRV	547					
FokI		136		518		554
HaeII		153				
HaeIII	206		210			
HgaI		431				
HhaI		77		152		413
HincII		319				
HinfI		520		598		
HinPII	75		150		411	
HpaII	50		57		207	310
HphI	71		469		529	
KpnI		219				
MaeI		314		372		
MaeII		114		405		
MaeIII	245		265		457	716
MboII	182		274		277	347
	497	653	661			
MnlI	54		282		531	627
	750					
MseI	41		237			
NaeI	208					
NciI		51		310		
NlaIII	264	397				
NlaIV	55		217			
NsiI		440				
NspHI	397					
PleI	592					
RsaI	69		167		217	
Sau3AI	172	613	678			
Sau96I	204	209				
ScrFI	51	213	310	384		
SfaNI	428					
TaqI 288	441	537	585			
XhoII	678					

Fig. 8

**Fig. 9 (Part 1 of 2)**



*Fig. 9 (Part 2 of 2)*

FIGURE 10



COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

the specification of which: *(check one)*

REGULAR OR DESIGN APPLICATION

- ☐ is attached hereto.
- ☐ was filed on _____ as application Serial No. _____
_____ and was amended on _____ (if
applicable).

PCT FILED APPLICATION ENTERING NATIONAL STAGE

- ☒ was described and claimed in International application No.
PCT/GB99/03654 filed on 5th November 1999

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under 35 USC 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

Country	Application Number	Date of Filing (day, month, year)	Priority Claimed
Great Britain	9824357.9	7 th November 1998	Yes

(Complete this part only if this is a continuing application.)

I hereby claim the benefit under 35 USC 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status—patented, pending, abandoned)

POWER OF ATTORNEY

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from **WYNNE-JONES, LAINE & JAMES** as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

As a named inventor, I hereby appoint the following attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: **Robert J. PATCH, Reg. No. 17,355, Andrew J. PATCH, Reg. No. 32,925, Robert F. HARGEST, Reg. No. 25,590, Benoît CASTEL, Reg. No. 35,041, Eric JENSEN, Reg. No. 37,855, and Thomas W. PERKINS, Reg. No. 33,027, c/o YOUNG & THOMPSON, Second Floor, 745 South 23rd Street, Arlington, Virginia 22202. Address all telephone calls to Young & Thompson at 703/521-2297.**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: **Anthony Keith CAMPBELL**
(given name, family name)

Inventor's signature

Date

Residence: **Penarth, United Kingdom**

Citizenship: **British**

Post Office Address: **14 Maillard's Haven, Penarth, Vale of Glamorgan, CF65 5RF, United Kingdom**

SEQUENCE LISTING

<110> CAMPBELL, ANTHONY KEITH

<120> PROTEIN AND DNA CODING THEREFOR

<130> WCM.69.US

<140> 09/831,142

<141> 2001-05-07

<150> PCT/GB99/03654

<151> 1999-11-05

<150> GB 9824357.9

<151> 1998-11-07

<160> 42

<170> PatentIn Ver. 2.1

<210> 1

<211> 870

<212> DNA

<213> Pholas dactylus

<220>

<221> CDS

<222> (30)..(704)

<400> 1

gaattcggca	cgagtcggaa	aagaacaaa	atg	gct	tgt	atc	ggt	ttc	ggt	gct	53
			Met	Ala	Cys	Ile	Val	Phe	Val	Ala	
			1				5				

ctt	gtc	gct	cta	tgc	tta	atg	caa	ccg	ggt	tcc	ggt	gag	gaa	gta	caa	101
Leu	Val	Ala	Leu	Cys	Leu	Met	Gln	Pro	Gly	Ser	Gly	Glu	Glu	Val	Gln	
10						15				20						

tgc	gcg	atg	aat	tgg	aca	caa	gct	aat	gaa	tat	gtg	ttc	aac	gtg	gac	149
Cys	Ala	Met	Asn	Trp	Thr	Gln	Ala	Asn	Glu	Tyr	Val	Phe	Asn	Val	Asp	
25					30				35					40		

tgg	atg	acc	att	ttc	atc	tac	gac	tat	ggc	gct	caa	gag	caa	ctg	tac	197
Trp	Met	Thr	Ile	Phe	Ile	Tyr	Asp	Tyr	Gly	Ala	Gln	Glu	Gln	Leu	Tyr	
			45						50					55		

gaa	gat	cgg	gct	ttg	ggg	ctg	tgt	cgg	att	gaa	cgg	gcc	ggc	cca	ggt	245
Glu	Asp	Arg	Ala	Leu	Gly	Leu	Cys	Arg	Ile	Glu	Arg	Ala	Gly	Pro	Gly	
			60					65					70			

acc	aca	aaa	gcc	gtc	tgg	att	aac	tgg	agt	aac	gac	acg	cag	tca	tgt	293
Thr	Thr	Lys	Ala	Val	Trp	Ile	Asn	Trp	Ser	Asn	Asp	Thr	Gln	Ser	Cys	
		75					80					85				

gta	aca	aga	aaa	aca	atc	ttc	ttc	gag	ggt	gga	gaa	att	gcc	cgg	341	
Val	Thr	Arg	Lys	Thr	Ile	Phe	Phe	Glu	Val	Gly	Gly	Glu	Ile	Ala	Arg	
		90				95				100						

cta gtt gac tac aga cca cag gaa gac gga act gag aaa act ttt aca 389
 Leu Val Asp Tyr Arg Pro Gln Glu Asp Gly Thr Glu Lys Thr Phe Thr
 105 110 115 120

aga aaa ttc tct agc aaa atg cca ggc act tac atg ctt atg gac gtg 437
 Arg Lys Phe Ser Ser Lys Met Pro Gly Thr Tyr Met Leu Met Asp Val
 125 130 135

tgc gct aca agg gac gct gat gat aaa tgc atc gaa ggc aca att gtg 485
 Cys Ala Thr Arg Asp Ala Asp Asp Lys Cys Ile Glu Gly Thr Ile Val
 140 145 150

gtg aca gtc agg gtg tcc cta tat gac gaa gat aac aat ggt gta atg 533
 Val Thr Val Arg Val Ser Leu Tyr Asp Glu Asp Asn Asn Gly Val Met
 155 160 165

gat gaa ggt aag gtg att cca tct gag aca atc gag gat gat atc aag 581
 Asp Glu Gly Lys Val Ile Pro Ser Glu Thr Ile Glu Asp Asp Ile Lys
 170 175 180

gac tgt ggg ctc tta gac caa gat gtt gaa ctc gat tat acg tgg act 629
 Asp Cys Gly Leu Leu Asp Gln Asp Val Glu Leu Asp Tyr Thr Trp Thr
 185 190 195 200

caa aac gag tgt gat cta cca gac aca gta gac gag gct gaa gac aca 677
 Gln Asn Glu Cys Asp Leu Pro Asp Thr Val Asp Glu Ala Glu Asp Thr
 205 210 215

ccg tca gaa act gga gaa ttc ttc tgg tagatctatc agactacttt 724
 Pro Ser Glu Thr Gly Glu Phe Phe Trp
 220 225

tatcagcagg acaactggtc gttaccagac acctataacg tgtcctcatc aataatgtgt 784

aaaacagaaa taatcgatag aatattgaaa ataaaatggt aataaacact gggttgaaata 844

tgaaaaaaaaaaaaaaaa ctcgag 870

<210> 2
 <211> 816
 <212> DNA
 <213> Pholas dactylus

<400> 2
 gaattcggca cgagggaaaa gaacaaaatg gcttgtatcg ttttcggtgc tcttgtcgct 60
 ctatgcttaa tgcaaccggg ttccggtgag gaagtacaat gcgcgatgaa ttggacacaa 120
 gctaataaat atgtgttcaa cgtggactgg atgaccattt tcatctacga ctatggcgct 180
 caagagcaac tgtacgagga tcgggctttg gggctgtgtc ggattgaacg ggccggccca 240
 ggtaccacaa aagccgtctg gattaactgg agtaacgaca cgcagtcacg tgtaacaaga 300
 aaaacaatct tcttcgaggt tgggtggagaa attgcccggc tagttgacta cagaccacag 360
 gaagacggaa ctgagaaaac ttttacaaga aaattctcta gcaaaatgcc aggcacttac 420
 atgcttatgg acgtgtgctc tacaaggac gctgatgata aatgcatcga aggcacaatt 480
 gtggtgacag tcaggggtgc cctatatgac gaagataaca atggtgtaat ggatgaagg 540
 aaggttattc catctgagac aatcgaggat gatatacagg actgtgggct cttagaccaa 600
 gatgttgaaac tcgattatac gtggactcaa aacgagtggt atctaccaga cacagtagac 660
 gaggtgaag acacaccgtc agaaactgga gaattcttct ggtagatcta tcagaccact 720
 tttatcagca ggacaactgg tcgttaccag acacctataa cgtgtcctca tcaataatgt 780

gtaaaacaga aataatcgat agaattattga aaataa

816

<210> 3
 <211> 852
 <212> DNA
 <213> Pholas dactylus

<400> 3
 gtcggaag aacaaatgg cttgtatcgt tttcgttgct cttgtcgctc tatgcttaat 60
 gcaaccgggt tccggtgagg aagtacaatg cgcgatgaat tggacacaag ctaatgaata 120
 tgtgttcaac gtggactgga tgaccatttt catctacgac tatggcgctc aagagcaact 180
 gtacgaggat cgggcttttg ggctgtgtcg gattgaacgg gccggcccag gtaccacaaa 240
 agccgtctgg attaactgga gtaacgacac gcagtcatgt gtaacaagaa aaacaatctt 300
 cttcgagggt ggtggagaaa ttgcccggct agttgactac agaccacagg aagacggaac 360
 tgagaaaact tttacaagaa aattctctag caaatgccca ggcacttaca tgcttatgga 420
 cgtgtgcgct acaagggacg ctgatgataa atgcatcgaa ggcacaattg tggtgacagt 480
 caggggtgtcc ctatatgacg aagataacaa tgggtgtaat gatgaaggta aggttattcc 540
 atctgagaca atcgaggatg atatcaagga ctgtgggctc ttagaccaag atgttgaact 600
 cgattatacg tggactcaaa acgagtgtga tctaccagac acagtagacg aggctgaaga 660
 cacaccgtca gaaactggag aattcttctg gtagatctat cagaccactt ttatcagcag 720
 gacaactggc cgttaccaga cacctataac gtgtcctcat caataatgtg taaaacagaa 780
 ataatcgata gaatattgaa aataaaatgt taatagacac tgggtgaaaa aaaaaaaaaa 840
 aaaaaactcg ag 852

<210> 4
 <211> 225
 <212> PRT
 <213> Pholas dactylus

<400> 4
 Met Ala Cys Ile Val Phe Val Ala Leu Val Ala Leu Cys Leu Met Gln
 1 5 10 15
 Pro Gly Ser Gly Glu Glu Val Gln Cys Ala Met Asn Trp Thr Gln Ala
 20 25 30
 Asn Glu Tyr Val Phe Asn Val Asp Trp Met Thr Ile Phe Ile Tyr Asp
 35 40 45
 Tyr Gly Ala Gln Glu Gln Leu Tyr Glu Asp Arg Ala Leu Gly Leu Cys
 50 55 60
 Arg Ile Glu Arg Ala Gly Pro Gly Thr Thr Lys Ala Val Trp Ile Asn
 65 70 75 80
 Trp Ser Asn Asp Thr Gln Ser Cys Val Thr Arg Lys Thr Ile Phe Phe
 85 90 95
 Glu Val Gly Gly Glu Ile Ala Arg Leu Val Asp Tyr Arg Pro Gln Glu
 100 105 110
 Asp Gly Thr Glu Lys Thr Phe Thr Arg Lys Phe Ser Ser Lys Met Pro
 115 120 125
 Gly Thr Tyr Met Leu Met Asp Val Cys Ala Thr Arg Asp Ala Asp Asp
 130 135 140

Lys Cys Ile Glu Gly Thr Ile Val Val Thr Val Arg Val Ser Leu Tyr
145 150 155 160

Asp Glu Asp Asn Asn Gly Val Met Asp Glu Gly Lys Val Ile Pro Ser
165 170 175

Glu Thr Ile Glu Asp Asp Ile Lys Asp Cys Gly Leu Leu Asp Gln Asp
180 185 190

Val Glu Leu Asp Tyr Thr Trp Thr Gln Asn Glu Cys Asp Leu Pro Asp
195 200 205

Thr Val Asp Glu Ala Glu Asp Thr Pro Ser Glu Thr Gly Glu Phe Phe
210 215 220

Trp
225

<210> 5
<211> 205
<212> PRT
<213> Pholas dactylus

<400> 5
Glu Glu Val Gln Cys Ala Met Asn Trp Thr Gln Ala Asn Glu Tyr Val
1 5 10 15

Phe Asn Val Asp Trp Met Thr Ile Phe Ile Tyr Asp Tyr Gly Ala Gln
20 25 30

Glu Gln Leu Tyr Glu Asp Arg Ala Leu Gly Leu Cys Arg Ile Glu Arg
35 40 45

Ala Gly Pro Gly Thr Thr Lys Ala Val Trp Ile Asn Trp Ser Asn Asp
50 55 60

Thr Gln Ser Cys Val Thr Arg Lys Thr Ile Phe Phe Glu Val Gly Gly
65 70 75 80

Glu Ile Ala Arg Leu Val Asp Tyr Arg Pro Gln Glu Asp Gly Thr Glu
85 90 95

Lys Thr Phe Thr Arg Lys Phe Ser Ser Lys Met Pro Gly Thr Tyr Met
100 105 110

Leu Met Asp Val Cys Ala Thr Arg Asp Ala Asp Asp Lys Cys Ile Glu
115 120 125

Gly Thr Ile Val Val Thr Val Arg Val Ser Leu Tyr Asp Glu Asp Asn
130 135 140

Asn Gly Val Met Asp Glu Gly Lys Val Ile Pro Ser Glu Thr Ile Glu
145 150 155 160

Asp Asp Ile Lys Asp Cys Gly Leu Leu Asp Gln Asp Val Glu Leu Asp
165 170 175

096444-0504

```

Met Ala Cys Ile Val Phe Val Ala Leu Val Ala Leu Cys Leu Met Gln
  1          5          10          15

Pro Gly Ser Gly Glu Glu Val Gln Cys Ala Met Asn Trp Thr Gln Ala
      20          25          30

Asn Glu Tyr Val Phe Asn Val Asp Trp Met Thr Ile Phe Ile Tyr Asp
      35          40          45

Tyr Gly Ala Gln Glu Gln Leu Tyr Glu Asp Arg Ala Leu Gly Leu Cys
      50          55          60

Arg Ile Glu Arg Ala Gly Pro Gly Thr Thr Lys Ala Val Trp Ile Asn
      65          70          75          80

Trp Ser Asn Asp Thr Gln Ser Cys Val Thr Arg Lys Thr Ile Phe Phe
      85          90          95

Glu Val Gly Gly Glu Ile Ala Arg Leu Val Asp Tyr Arg Pro Gln Glu
      100          105          110

Asp Gly Thr Glu Lys Thr Phe Thr Arg Lys Phe Ser Ser Lys Met Pro
      115          120          125

Gly Thr Tyr Met Leu Met Asp Val Cys Ala Thr Arg Asp Ala Asp Asp
      130          135          140

Lys Cys Ile Glu Gly Thr Ile Val Val Thr Val Arg Val Ser Leu Tyr
      145          150          155          160

Asp Glu Asp Asn Asn Gly Val Met Asp Glu Gly Lys Val Ile Pro Ser
      165          170          175

Glu Thr Ile Glu Asp Asp Ile Lys Asp Cys Gly Leu Leu Asp Gln Asp
      180          185          190

Val Glu Leu Asp Tyr Thr Trp Thr Gln Asn Glu Cys Asp Leu Pro Asp
      195          200          205

Thr Val Asp Glu Ala Glu Asp Thr Pro Ser Glu Thr Gly Glu Phe Phe
      210          215          220

Trp
225

```

<210> 7
 <211> 17
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<220>
 <221> modified_base
 <222> (3)
 <223> i

<400> 7
 acnathhtyt tycargt

17

<210> 8
 <211> 17
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<220>
 <221> modified_base
 <222> (12)
 <223> A, T, C or G

<220>
 <221> modified_base
 <222> (15)
 <223> i

<400> 8
 cargargarg gnacnga

17

<210> 9
 <211> 17
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<220>
 <221> modified_base
 <222> (3)
 <223> i

TOC50-05001

```
<400> 9
tcngtnccyt cytcytg
```

```
<210> 10
<211> 18
<212> DNA
<213> Artificial sequence
```

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

```
<220>
<221> modified_base
<222> (9)
<223> i
```

```
<400> 10
ttyaaygtng aytggatg
```

```
<210> 11
<211> 20
<212> DNA
<213> Artificial sequence
```

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

```
<400> 11
acacagcccc aaagcccgat
```

```
<210> 12
<211> 20
<212> DNA
<213> Artificial sequence
```

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 12
ttgcccggct agttgactac

```
<210> 13
<211> 24
<212> DNA
<213> Artificial sequence
```


<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 13

catatttcaa ccagtgttta ttaa

24

<210> 14

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 14

caattgtgcc ttcgatgca

19

<210> 15

<211> 17

<212> DNA

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 15

ggactgtggg ctcttag

17

<210> 16

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 16

atggcttgta tcgttttcgt

20

<210> 17

<211> 27

<212> DNA

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

09344-0504
F06050 247880

<400> 17
ccacacggat cctgaggaag tacaatg

27

<210> 18
<211> 27
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 18
ccacacggat ccttattgat gaggaca

27

<210> 19
<211> 53
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19
cttggttttta tggctgtcta catttcttac atctatgcgg aggaagtaca atg

53

<210> 20
<211> 54
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 20
ccacacagat ctagaatgaa attcttagtc aacgttgccc ttgtttttat ggtc

54

<210> 21
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 21
tttactgttt tcgtaacagt tttg

24

<210> 22
<211> 20

0903144-05004
T0C050-24T050

<212> DNA
 <213> Artificial sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 22

caacaacgca cagaatctag

20

<210> 23

<211> 726

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Clone 40
 amplified by rTth DNA pol XL

<220>

<221> modified_base

<222> (644)

<223> A, T, C, G, other or unknown

<400> 23

tatgcttaat	gcaaccgggt	tccgggtgagg	aagtacaatg	cgcgatgaat	tggacacaag	60
ctaataaata	tgtgttcaac	gtggactgga	tgaccatttt	catctacgac	tatggcgctc	120
aagagcaact	gtacgaagat	cgggcttttg	ggctgtgtcg	gattgaacgg	gccggcccag	180
gtaccacaaa	agccgtcttg	attaactgga	gtaacgacac	gcagtcattg	gtaacaagaa	240
aaacaatctt	cttcgagggt	ggtggagaaa	ttgcccggct	agttgactac	agaccacagg	300
aagacggaac	tgagaaaact	tttacaagaa	aattctctag	caaaatgcca	ggcacttaca	360
tgcttatgga	cgtgtgcgct	acaagggacg	ctgatgataa	atgcacgaa	ggcacaattg	420
tggtgacagt	caggggtgtc	ctatatgacg	aagataacaa	tggtgtaatg	gatgaaggta	480
aggtgattcc	atctgagaca	atcgaggatg	atatcaagga	ctgtgggctc	ttagaccaag	540
atgttgaact	cgattatacg	tggactcaaa	acgagtgtga	tctaccagac	acagtagacg	600
aggctgaaga	cacaccgtca	gaaactggag	aattcttctg	gtanatctat	cagactactt	660
ttatcagcag	gacaactggg	cgttaccaga	cacctataac	gtgtcctcat	caataatgtg	720
taaaac						726

<210> 24

<211> 34

<212> PRT

<213> *Saccharomyces cerevisiae*

<400> 24

Asn	Leu	Arg	Asp	Glu	Asp	Asn	Asn	Leu	Leu	Asp	Glu	Asn	Gly	Asp	Leu
1					5				10					15	

Leu	Pro	Leu	Glu	Ser	Leu	Glu	Leu	Asp	Gln	Asp	Val	Glu	Leu	Asp	Tyr
			20					25						30	

Thr Trp

<210> 25

<211> 31

090314H 050304

<212> PRT

<213> *Cyprinus carpio*

<400> 25

Ile Met Gln Lys Gly Glu Leu Val Pro Leu Asp Thr Val Leu Asp Met
1 5 10 15

Ile Lys Asp Ala Met Ile Ala Lys Ala Asp Val Ser Lys Gly Tyr
20 25 30

<210> 26

<211> 20

<212> PRT

<213> *Synechocystis* sp.

<400> 26

Asp Gln Val Gln Ser Leu Met Arg Phe Ser Gln Ser Lys Gln Ile Ile
1 5 10 15

Phe Asn Phe Asp
20

<210> 27

<211> 14

<212> PRT

<213> *Emericella nidulans*

<400> 27

Ile Met Cys Ser Val Asp Trp Thr Arg Arg Asn Arg Phe Ile
1 5 10

<210> 28

<211> 14

<212> PRT

<213> *Drosophila melanogaster*

<400> 28

Pro Asp Thr Tyr Asp Glu Glu Glu Asp Thr Tyr Thr His Thr
1 5 10

<210> 29

<211> 13

<212> PRT

<213> *Peptococcus niger*

<400> 29

Asp Pro Ile Asp Glu Ala Gly Glu Val Pro Ser Glu Thr
1 5 10

<210> 30

<211> 25

<212> PRT

<213> *Homo sapiens*

0903442-050304

<400> 30

Asp Asp Asp Gly Ile Gly Tyr Val Glu Asp Gly Arg Glu Ile Phe Asp
 1 5 10 15

Asp Asp Leu Glu Asp Asp Ala Leu Asp
 20 25

<210> 31

<211> 59

<212> PRT

<213> Vargula sp.

<400> 31

Tyr Trp Asn Thr Trp Asp Val Lys Val Ser Leu Arg Asp Val Glu Ser
 1 5 10 15

Tyr Thr Glu Val Glu Lys Val Thr Ile Arg Lys Gln Ser Thr Val Val
 20 25 30

Asp Leu Ile Val Asp Gly Lys Gln Val Lys Val Gly Gly Val Asp Val
 35 40 45

Ser Ile Pro Tyr Ser Ser Glu Asn Thr Ser Ile
 50 55

<210> 32

<211> 62

<212> PRT

<213> Renilla sp.

<400> 32

Ala Ile Lys Ile Ala Lys Leu Ser Ala Glu Lys Ala Glu Glu Thr Arg
 1 5 10 15

Gly Phe Leu Arg Val Ala Asp Gln Leu Gly Leu Ala Pro Gly Val Arg
 20 25 30

Ile Ser Val Glu Glu Ala Ala Val Asn Ala Thr Asp Ser Leu Leu Lys
 35 40 45

Met Lys Ala Glu Glu Lys Ala Met Ala Val Ile Gln Ser Leu
 50 55 60

<210> 33

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Illustrative
 P-loop binding motif

096344-05001

```
<400> 37
Met Leu Leu Pro Val Pro Leu Leu Leu Gly Leu Leu Gly Leu Ala Ala
  1             5             10             15
```

<210> 38
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
illustrative peptide

<400> 38
Lys Asp Glu Leu
1

<210> 39
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
illustrative peptide

<400> 39
His Asp Glu Leu
1

<210> 40
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
illustrative peptide

<400> 40
Lys Glu Glu Leu
1

<210> 41
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
illustrative peptide

<400> 41
Pro Lys Lys Lys Arg Lys Val
1 5

0903142-0504
F04050-247E060

<210> 42
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Illustrative
N-terminal acylation motif from Tyrosine kinase

<400> 42
Met Gly Cys Val Cys Ser Ser Asn Pro Asp
1 5 10

090314h.0507.04
TOCOSO"CHTTEGO